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1 Abbreviations 
χ² Pearson’s Chi-Square 
∆ delta 
µg microgramme 
µSv Microsievert 
AGA appropriate (weight and height) for gestational age (at birth) 
BA bone age (years) 
BIA bioelectrical impedance analysis 
BMC bone mineral content 
BMI  body mass index 
CA chronological age (years) 
cm² square centimetre 
cm³ cubic centimetre 
CSA cross-sectional area 
d day 
DXA-scan dual-energy X-ray absorptiometry scan 
ELBW extremely low birth weight 
EMEA  European Agency for the Evaluation of Medicinal Products 
EPH-gestosis edema-proteinuria-hypertension-gestosis 
et al.  et alii 
FDA Food and Drug Administration 
g gramme 
GH growth hormone 
GHD growth hormone deficiency 
HOMA2-IR homeostatic model assessment for insulin resistance index, 
version 2 
IGF-1 Insulin-like growth factor-1 
IGFBP-3 Insulin-like growth factor binding protein-3 
Inc. incorporation 
J. Jahre (German for years) 
keV kiloelectrovolt 
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kg Kilogramme 
L Litre 
MA muscle area 
mg Milligramme 
MI Michigan 
MIGF maximal isometric grip force 
mL Millilitre 
mm Millimetre 
mm² square millimetre 
mm⁴ millimetre to the fourth 
mo. Months 
N Newton 
n Number 
NC North Carolina 
ng Nanogramme 
p level of significance 
P3 third percentile 
PGR preterm growth restraint 
pQCT peripheral quantitative computer tomography 
R Resistance 
R² coefficient of determination of a linear regression 
RIA radio immuno assay 
SDS standard deviation score 
SD standard deviation 
SGA small (weight or height) for gestational age (at birth) 
SSI Strength-Strain-Index 
SRS Silver-Russel-Syndrome 
Std Err. standard error 
vBMD volumetric bone mineral density 
vBMDmax maximum volumetric bone mineral density 
vBMDvox volumetric bone mineral density in the voxel 
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VLBW very low birth weight (weight below 1500 g at birth) 
vs. Versus 
Xc Reactance 
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2 Introduction 
2.1 Prematurity 
Preterm birth has been defined by the World Health Organization (WHO) as a 
birth before 37 weeks of gestation and extremely preterm birth before 28 weeks 
of gestation with a further distinction between three subgroups (preterm: < 37 
weeks of gestation; very preterm: < 32 weeks of gestation and extremely 
preterm: < 28 weeks of gestation 1. The term small for gestational age (SGA) 
has been used to describe a lack of fetal growth in relation to duration of 
pregnancy and has been defined by the WHO as having weight and length 
below the 10th percentile for gestational age 2. It has been recommended to 
express birth length and weight in terms of standard deviation scores (SDS) and 
a birth weight and/or birth length of -2 SDS or lower for gestational age has 
been proposed as the criterion for SGA 3. 
Low birth weight (LBW) has been defined by the WHO as a birth weight below 
2500 g, very low birth weight (VLBW) below 1500 g and extremely low birth 
weight (ELBW) below 1000 g 4. 
Children born very low birth weight (VLBW, defined here as having a birth 
weight < 1500 g) are differentiated into AGA or SGA according to whether they 
were born with a weight and/or height above (AGA) or below (SGA) -2 SDS 
according to a defined reference.  
2.2 Growth retardation and catch-up growth 
Preterm AGA children born VLBW may suffer extra-uterine growth restraint 
(EUGR) in their early neonatal life comparable to the situation of a fetus in utero 
with placental insufficiency 5,6. Children born VLBW show a similar growth 
pattern during childhood, irrespective of whether they were appropriate (AGA) 
or small for gestational age (SGA) at birth 7. Most of these children show catch-
up growth up to or above the third percentile (P3) of height within the first two 
years of age. It has been shown that birth weight SDS is a significant predictor 
for catch-up growth in SGA children irrespective of their gestational age 8. 
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Preterm born children show a substantial growth failure in their early postnatal 
period. The majority shows catch-up growth until 2-3 years of age and in some 
cases until adolescence. Preterm growth restraint leads in one out of five 
children to long-term impairments independent of the perinatal stage at which 
the growth restraint happened 7. SGA children tend to be short at the age of 5 
or 6 years if their height and/or weight gain in the first year of life was poor, 
especially if their parents were also short. The same applies to VLBW children 
born AGA with poor height and/or weight gain in the first two years of life 9. On 
average most preterm born infants remain shorter and lighter than term-born 
infants during their growth period. An altered body composition in adulthood 
may be the result of disproportionate catch-up growth, though early catch-up 
growth is beneficial for neurodevelopmental outcome 10. 
Those lacking catch-up growth after reaching two years of age with a current 
length below -2.5 SD need further investigation 3. Growth hormone (GH) 
treatment can be prescribed for SGA children who remain very short while no 
indication has been established for AGA children 3, 11. 
Small preterm born children lacking catch-up growth appear to have reduced 
adult height, strength and motor capacity 7, 12, 10, 13, 14. An altered body 
composition with reduced muscle tissue and increased fat tissue implicating an 
increased risk for cardiovascular diseases has been reported for preterm born 
children 10, 15, 16, 17, 18. 
2.3 Aim 
The aim of this study is to examine body composition and growth at start and 
after one year of GH treatment of short children born with a birth weight under 
1500 g (VLBW). GH therapy appears to be an effective therapy to reduce adult 
height deficit in short SGA children who do not show satisfying catch-up growth 
11. We hypothesize that the effect of GH on height gain, muscle mass and 
strength as well as bone density and geometry would be similar in the AGA and 
SGA groups. 
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3 Patients and Methods 
3.1 Patients 
The patient group with a total of 50 short prepubertal children born VLBW 
comprised 19 short children born SGA (6 girls) and 31 short children born AGA 
(15 girls), classified according to the reference values of Niklasson et al. 19. Six 
children had to be excluded from the study because they were unable to take 
part in the starting examination and after 12 months of GH therapy, leaving a 
study group of 44 children with complete data of pQCT measurements at start 
and after twelve months of GH therapy. Due to movement artefacts, the pQCT 
data of arm measurements was only usable in 41 children (arm pQCT) and the 
pQCT data of leg measurements in 37 children (leg pQCT), respectively (see 
TABLE 1). In the interest of better readability TABLE 1 to 3 are placed in the 
text, all further tables are given in the appendix. 
 
TABLE 1: Study group 
 
SGA AGA Total 
N (girls) 19 (6) 31 (15) 50 (21) 
Complete data pQCT arm or leg 0+12 months 17 (6) 27 (12) 44 (18) 
Complete data pQCT arm and leg 0+12 months 14 (4) 20 (8) 34 (12) 
Complete data pQCT arm 0+12 months 16 (6) 25 (10) 41 (16) 
Complete data pQCT leg 0+12 months 15 (4) 22 (10) 37 (14) 
 
This longitudinal follow-up study was performed in the Department of Pediatric 
Endocrinology and Diabetology of Tübingen University Children’s Hospital. All 
children followed clinical investigations and anthropometrical measurements 
during the course of the study. Perinatal parameters were gathered from the 
patient’s medical charts. Inclusion criteria were a birth weight below 1500 g and 
an insufficient catch-up growth (height velocity < 0 SDS) with height at start of 
treatment being -2 SDS or lower and at least 1 SDS below target height SDS. 
GH deficiency (GHD) was excluded by a GH peak above 8 µg/L in an arginine 
test or an overnight GH secretion profile. 
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Mean GH dose did not differ significantly between groups: 54 µg/kg/d 
(SD 12 µg/kg/d) in the AGA group and 51 µg/kg/d (SD 11 µg/kg/d) in the SGA 
group (p = 0.44).  
Six children suspected with Silver-Russell-Syndrome were included in the study 
group with one boy and two girls in each group. Their values at start and during 
treatment did not differ from the rest of the respective groups. Data on genetic 
tests were complete in one SGA girl, one AGA girl and the AGA boy. The SGA 
girl was diagnosed with a maternal UPD 7 (uniparental disomy of chromosome 
7). The second SGA girl presented with a triangular face, a clinodactyly at both 
hands and an asymmetric growth with shortening of the left hand and foot. The 
SGA boy was born as a second twin and showed a massive teeth 
misalignment, asymmetric growth with shortened left arm and leg, a big head 
with a slim mandible, clinodactyly and a discrete left-sided spasm.  
A maternal UPD 7 was excluded in the first AGA girl. She presented with a 
typical face for Silver-Russel-Syndrome, an implied funnel chest, thin hair, 
purulent rhinitis, visual impairment, adenoids and overall retarded dystrophic 
development with reduced concentration. The second AGA girl suspected with 
SRS showed a triangular face, an inverse hairline, a relatively big head with a 
broad nose bridge, a pectus excavatum, frequent tonsillitis and a high frequency 
sensorineural hearing loss. The AGA boy showed no maternal UPD 7 and no 
epimutation in ICR1 (imprinted control region 1) in 11p15 (chromosome 11, 
allele 15). Phenotypically he presented with a hunchback, clinodactyly of the 
fifth finger on both hands, a small mouth with hanging mouth angles, a high 
voice, tooth misalignment, mandibular rethrognathism, thin hair and syndactyly 
of second and third toe at both feet.  
We thus cannot be sure that all six of these children diagnosed with SRS 
actually had SRS, especially since the known mutations for SRS only account 
for 70% of the known cases. TABLE 2 shows prenatal and perinatal data as 
well as further medical conditions of the examined children. 
There was significant difference between the groups with regard to respiratory 
distress syndrome, duration of assisted ventilation and bronchopulmonary 
dysplasia. 
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Pregnancy risks such as multiple pregnancy, placental insufficiency and 
hydramniosis occurred in both groups likewise, whereas amniotic infection 
syndrome occurred more often in the AGA group and EPH-gestosis in the SGA 
group. Maternal smoking may be underreported with only one reported case in 
the SGA group. Respiratory distress syndrome and subsequent 
bronchopulmonary dysplasia occurred more often in the AGA group. There was 
a high prevalence of assisted ventilation in the AGA group. Perinatal infections 
occurred more often among the SGA children, whereas cases of necrotizing 
enterocolitis and enteropathic acrodermatitis have only been reported in the 
AGA group. Cerebral malformations, further dysplasias and minor anomalies 
occurred more often in the AGA group. One case of intracranial hemorrhage 
and one of internal hydrocephalus were reported among the SGA children. 
Pearson’s Chi-square analysis shows a significant difference between the 
groups with regard to the parameters: duration of assisted ventilation (> 7 days 
on assisted ventilation), respiratory distress syndrome (both with p = 0.00040) 
and bronchopulmonary dysplasia with p = 0.040. On the other hand results with 
p > 0.05 do not necessarily assure that there is no difference between groups. 
 
TABLE 2: Prenatal and perinatal characteristics and clinical conditions: number of 
children with the respective condition with Pearson’s χ² and p 
Characteristic SGA AGA Total Pearson χ² Prob > χ² 
N 17 27 44     
Before birth (%)           
Maternal smoking 1 0 1 1.6 0.20 
Parity > 0 3 8 11 0.80 0.37 
Multiple pregnancy 5 6 11 0.29 0.59 
Amniotic infection 
syndrome 1 5 6 1.4 0.23 
Placental 
insufficiency/Hydramniosis 7 8 15 0.62 0.43 
Preterm abruption of 
placenta 2 6 8 0.77 0.38 
EPH-gestosis 4 3 7 1.2 0.27 
            
At or after birth           
Respiratory distress 
syndrome 1 16 17 12.5 0.00040 
> 7 days on assisted 2 18 20 12.7 0.00040 
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ventilation 
Bronchopulmonary 
dysplasia 2 11 13 4.2 0.040 
Pneumothorax 0 2 2 1.3 0.25 
Sepsis/Infection 8 7 15 2.1 0.15 
Necrotizing enterocolitis 0 3 3 2.0 0.15 
Enteropathic acrodermatitis 0 1 1 0.64 0.42 
Hyperbilirubinemia 2 3 5 0.0040 0.95 
Cholestasis 1 1 2 0.11 0.74 
Transfusion-dependent 
anemia 9 11 20 0.63 0.43 
Intracranial hemorrhage 1 0 1 1.6 0.20 
Internal hydrocephalus 1 0 1 1.6 0.20 
Cerebral palsy 1 2 3 0.038 0.85 
Cerebral malformation 0 3 3 2.03 0.15 
Hypoplastic 
adenohypophysis 1 2 3 0.038 0.85 
Convulsions 0 1 1 0.64 0.42 
Dysplasias/minor anomalies 5 14 19 2.1 0.14 
Hernias 10 8 18 3.7 0.055 
Heart malformations 3 3 6 0.38 0.54 
Silver-Russell syndrome 3 3 6 0.38 0.54 
 
The study was approved by the independent ethics committee of the medical 
faculty of the University of Tubingen and informed written consent was given by 
the parents. 
3.2 Methods 
At start of GH treatment and at intervals of 6 and 12 months measurements of 
height, weight and body composition were done for all 44 children (with further 
measurements at 24, 36, and 48 months in some children). SDS values for 
height and weight were calculated according to the standards of Prader et al. 20. 
Birthweight SDS calculations were done according to given standards by 
Niklasson et al. 19. Bone age was estimated according to the method of Greulich 
and Pyle 21. Muscle strength was measured by the use of maximal isometric 
grip force (MIGF) of the non-dominant hand (Newton; N) using an adjustable 
Jamar dynamometer (Preston, Jackson, MI).  
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Body composition data on fat-, muscle-, bone-mass and body-water were 
measured using a DXA body scan. Skinfold thickness was measured at the 
lower arm, calf, hip and scapula using a Holtain/Tanner-Whitehouse Skinfold 
Caliper. Measurements of Resistance R (Ohm) and Reactance Xc (Ohm) were 
obtained by Bioelectrical Impedance Analysis (BIA). 
IGF-1 values were measured at start, 3, and 6 months and every 6 months 
thereafter. The children in this cohort were receiving a relatively high GH dose 
of 55 µg/kg/d. This dose was thought to be appropriate because it was between 
the low and high dose used by de Zegher et al. 11 and because the first years of 
treatment were thought to offer the highest chance of catch-up: one did not 
want to waste time titrating upwards. This GH dose was reached in increments 
4 weeks after starting treatment and then titrated according to IGF-1 levels and 
reduced if IGF-1 was above +2 SDS (this was necessary in 4 children born SGA 
and 1 child born AGA). TABLE 3 shows the mean adjusted GH dose given from 
six months on for the following six months. (SGA children are now usually 
started at 33 µg/kg/d and titrated to a maximum of 50 µg/kg/d in our institution if 
they are not responding.) 
Fasting glucose, insulin and C-peptide were determined from venous blood 
samples in the basal fasting state between 8-10 a.m. in the morning. 
Homeostatic model assessment of insulin resistance (HOMA-IR) is an index of 
the steady state beta cell function and insulin sensitivity from basal fasting 
glucose and insulin or C-peptide measurements. Using C-peptide instead of 
insulin makes the calculations more stable to momentary changes in fasting 
blood insulin results. HOMA2-IR was calculated using the computerized 
HOMA2 calculator, as described by Wallace et al. 22.  
3.2.1 pQCT measurement 
The cross-sectional areas of muscle and fat were measured by pQCT (XCT 
2000 (Stratec, Inc., Pforzheim, Germany) on the proximal non-dominant lower 
arm and leg. The position was exactly 65% of the ulna length (55 % of the tibia 
length for leg) away from the radius growth plate (tibia growth plate for leg). A 
scout-view scan enabled a precise location of the radius/tibia growth plate. A 
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2 mm thick single tomographic slice was taken at a voxel size of 0.4 x 0,4 x 
2 mm³. The outer and inner cortical bone contours were detected at a threshold 
of 710 mg/cm³. The threshold of 30-70 mg/cm³ was used to measure muscle 
cross-section area and the remaining subcutaneous tissue constituted the fat 
area. The software package of Stratec, Inc. (version 6.0) was used for 
performing all image processing and calculations of numerical values. A single 
scan uses a radiation dose of approximately 0.3 µSv. The effective dose for the 
forearm is about 0.1 µSv, which is less than 2% of the effective natural 
background radiation dose acquired within one day (6.6 µSv). The calibration of 
the pQCT device was done once per week with a standard phantom and once 
per month with a cone phantom provided by the manufacturer. The low energy 
X-ray tube of the scanner is of 28 keV. A relative length of the arm was chosen 
(and the lengths of the radius and tibia were measured anew each time) to 
ensure exact corresponding measurements regardless of individual and 
interindividual changing arm lengths. Age- and height-dependent reference 
values for healthy German children have been established for the 65% site of 
the ulna length using the same pQCT device by Rauch and Schoenau 23. 
Corresponding reference values for the 65% site of the tibia length in healthy 
children have not yet been established. pQCT measurements of the leg were 
only done for a subset of 15 SGA children (4 girls) and 22 AGA children (10 
girls). 
 
The following offers a brief description of the main parameters measured: 
Muscle CSA [mm²] is used as a surrogate marker for muscle force and can be 
used to study the relationship between muscle and bone tissue 23. 
Total CSA [mm²] is the area of the entire bone cross-section which consists of 
cortical bone and marrow cavity. It is a measure of the outer bone size. 
Assuming a circular bone size it is also possible to calculate total CSA by using 
the periosteal perimeter, whereas the direct measurement of total CSA is more 
precise. 
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Total CSA is a key determinant of diaphyseal bending strength and is therefore 
one of the most important parameters of pQCT analysis. It is only influenced by 
periosteal apposition 23. 
Cortical CSA [mm²] is the surface area of cortical bone cross-section and is 
equivalent to total CSA minus marrow CSA. Cortical CSA changes under 
periosteal apposition and endocortical resorption 23. 
Cortical thickness [mm] is the width of the bone cortex and it changes under 
periosteal apposition and endocortical resorption. 
Total vBMD [mg/cm³] is the ratio of Bone mineral content (BMC) [mg/mm] and 
total CSA [mm²] of a bone. Bone mineral content is the mass of mineral per 1 
mm of axial bone length. BMC in pQCT measurements is influenced by 
periosteal, intracortical and endocortical changes. The bone mineral of 
diaphyseal bone is only situated in the cortex and therefore total vBMD is the 
product of cortical vBMD and the ratio between cortical CSA and total CSA 23. 
Cortical content [mg/mm] is the mass of mineral in the cortex per 1 mm of 
axial bone length. 
Cortical volumetric bone mineral density [mg/cm³] (Cortical vBMD) 
represents the density of the solid cortex. It is influenced by intracortical 
remodeling where old material with higher density is replaced by new bone 
material with lower density. Cortical vBMD can be used as a parameter of 
cortical porosity. The interpretation of cortical vBMD is limited by the partial 
volume effect in pQCT measurements. On the outer and inner surface the 
voxels are not completely filled, which leads to an underestimation of cortical 
vBMD in thinner cortices. The age-dependent reference values for cortical 
vBMD are only useful in normal parameters for cortical thickness 23. 
The polar moment of inertia [mm⁴] is the sum of all bone-filled voxel areas 
multiplied by the respective voxel’s distance from the center 23. 
The Strength-Strain-Index [mm³] is the polar moment of inertia divided by the 
maximal distance of a bone-filled voxel from the center (Section modulus) 
multiplied by the ratio of volumetric bone mineral density in the voxel 
(vBMDvox) [mg/cm³] and maximum mineral density under physiological 
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conditions (vBMDmax: 1200 mg/cm³). It is influenced by changes of bone 
mineralization and is a parameter of bone strength 23.  
Fat area [mm²] measured in pQCT is the subtraction of total area [mm²] minus 
muscle area [mm²] and total bone area [mm²]. 
Muscle density [mg/mL] measured in pQCT is expressed in mg per measured 
volume. 
3.2.2 DXA measurement 
Basic theory and methodology of DXA for measuring body composition 
The method of DXA (dual x-ray absorptiometry) is based on the degrees of 
attenuation of two different beam energies (6.4 and 11.2 fJ) that pass through 
the body. The degree of attenuation is dependent on the mass and type of 
tissue the energy beams pass through. For bone minerals the mass attenuation 
coefficients for both beam energies are known constants. For soft tissue the 
ratio of the mass attenuation coefficients varies linearly according to the fat 
fraction. In a region of interest the ratio for soft tissue is calculated in all pixels 
which contain only soft tissue and is then averaged. In a second step the ratio 
for soft tissue is extrapolated to the pixels containing both soft and bone tissue, 
based on the assumption that the soft-tissue composition in these pixels is 
similar. Total body bone mineral (TBBM) and soft tissue mass (STM) are then 
calculated. TBBM divided by the summarized area of bone containing pixels 
gives the total body bone mineral density (TBBD). Fat tissue mass (FTM) and 
lean tissue mass (LTM) are calculated from the STM and the fat percentage of 
the soft tissue deduced from the ratio of soft tissue. Lean body mass (LBM) is 
the sum of LTM and TBBM. Fat percentage of the body (FAT%) is FTM divided 
by the sum of LBM and FTM 24. 
In DXA bone mineral content (BMC) is calculated in a different way than in 
pQCT. In DXA BMC refers to the amount of mineral in the bone regions studied 
(mg/mm2). This is influenced by bone length or the size of the analyzed region. 
In pQCT BMC is the mass of mineral per axial bone length and area (mg/mm3): 
The calculations of pQCT BMC are therefore not prone to biases caused by the 
size of the bones 23. 
 
19 
 
  
3.2.3 Assays 
An in-house RIA was used for measuring GH in serum 25, the variation of the 
intraassay and interassay coefficients were less than 10%. Serum levels of IGF-
I and IGF-binding protein (IGFBP)-3 were measured by RIA as described by 
Blum et al. 26. The mean interassay and intraassay coefficients of the IGF-I and 
the IGFBP-3 assays were lower than 10%. Data were transformed into age-
related SDS values on the basis of a reference population of healthy German 
and Danish children with normal height 26. 
3.2.4 Statistics 
Statistical analyses were done by Dipl. med. Cornelia Berndt and Prof. Dr.  
David Martin using the computed statistics program JMP version 8.0.1 (SAS 
Institute, Cary, NC). Results are expressed in means and SD, unless otherwise 
specified. Significance of differences was tested with a two-tailed paired t test. A 
comparative study of both patient groups AGA and SGA was done by a two-
tailed unpaired t test. Differences were considered significant below the 5% 
level. Due to the explorative-descriptive nature of the statistics with a total of 
212 t-tests (136 two-tailed paired t tests and 76 two-tailed unpaired t tests), a 
Bonferroni-correction was not performed. Regression analyses were done using 
Pearson’s coefficient of correlation. Chi-square analyses to test differences 
between birth-parameters were done using contingency tables and results are 
given in Pearson’s Chi-square. The standard deviation scores (SDS) refer to the 
age- and sex-matched references, unless otherwise specified and were 
calculated as subject-value minus mean of age- and sex-matched reference 
divided by the standard deviation (SD) of age- and sex-matched reference. 
Calculations for height-dependent SDS for the given pQCT measurements were 
done according to the standards of Rauch and Schoenau 23 and for height-age 
SDS according to Schweizer et al. 27. 
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4 Results 
4.1 Baseline characteristics 
There were, by definition, significant differences between the AGA and SGA 
children with regard to gestational age (p < 0.0001), birth weight SDS 
(p < 0.0001) and birth length SDS (p < 0.0001). No significant differences 
between groups were found in the auxological characteristics at start of GH and 
in the GH dose (see TABLE 3, TABLE 4, TABLE 5 and TABLE 6). 
 
TABLE 3: Perinatal and auxological parameters at start of therapy (see TABLE 4, TABLE 
5 and TABLE 6 for the remaining parameters) with an unpaired t-test analysis between 
AGA and SGA. 
Perinatal and auxological 
parameters at GH start 
AGA (n = 27) SGA (n = 17) 
AGA vs. 
SGA 
Mean SD Mean SD p Value 
Gestational age (weeks) 29 2.2 33 2.4 <0.0001 
Birth weight (g) 1003 258 948 304 0.54 
Birth weight (SDS) -0.96 0.63 -3.2 0.89 <0.0001 
Birth length (SDS) -0.38 3.3 -3.5 1.1 <0.0001 
Height (SDS) -3.3 0.84 -3.3 0.73 1 
Max. GH in test (µg/L) 10 5.9 11 5.4 0.51 
GH dose (µg/kg/d) (6 mo) 54 12 51 11 0.44 
Height SDS (0 mo) – Target 
height SDS -2.7 0.80 -2.8 1.1 
 
0.75 
 
TABLE 2 shows the pre- and perinatal conditions of most of the children, where 
the medical chart was available. Comparison of pre- and perinatal conditions 
showed differences between the groups with 16 cases of respiratory distress 
syndrome being reported in the AGA group and only one case in the SGA 
group. Two cases of more than seven days on assisted ventilation after birth 
are reported in the SGA group, compared to 18 cases among the AGA group. 
Eleven cases of bronchopulmonary dysplasia are reported among the AGA 
group with only two cases in the SGA group respectively. Unfortunately medical 
charts of pre- and perinatal conditions were incomplete in two SGA girls and 
one AGA boy. One SGA girl was born in gestational week 31 as a third triplet at 
a birth weight of 600 g (-3.8 SDS). The second SGA girl was born in gestational 
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week 36 at a birth weight of 1480 g (-3.24 SDS). The AGA boy was born at a 
gestational age of 30 weeks at a birth weight of 1290 g (-0.41 SDS). He 
developed a postnatal sepsis and suffers from cerebral palsy.  
4.2 Changes in auxology during GH treatment 
The changes in auxological and endocrinological characteristics during the first 
year of GH therapy in AGA and SGA in a paired t-test analysis and a 
comparison between groups in an unpaired t-test are given in TABLE 4, TABLE 
5 and TABLE 6. 
The increase in height, height SDS, height velocity and height velocity SDS in 
both groups were all highly significant with p < 0.001. The increase in weight 
was highly significant in both groups and increase in weight SDS in SGA with 
p < 0.001, increase in weight SDS in AGA was significant with p < 0.001. 
Decrease in skinfold thickness measured at the triceps was significant in AGA 
with p = 0.0029, highly significant in SGA with p < 0.001. MIGF of the non-
dominant hand increased significantly in AGA with p < 0.001, in SGA with 
p = 0.0018. MIGF SDS of the non-dominant hand did not show any significant 
changes in both groups. Resistance R (BIA) decreased significantly in both 
groups with p < 0.001. Bone age changed significantly only in AGA with 
p < 0.001. Reactance Xc decreased significantly only in AGA with p = 0.048.  
No significant differences between both groups at start, in the changes of the 
first year of GH and after twelve months of treatment were found in the 
auxological characteristics (TABLE 6). 
4.3 Changes in endocrinology during GH treatment 
Increase in IGF-1, IGF-1 SDS and IGFBP-3 were all highly significant in both 
groups with p < 0.001. IGFBP-3 SDS increased highly significant in AGA with 
p < 0.001, in SGA with p < 0.001.  
Changes in insulin, C-peptide, glucose, plasma glucose and HOMA2-IR did not 
show any significance in both groups (see TABLE 4, TABLE 5 and TABLE 6). 
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4.4 Changes in pQCT parameters during GH treatment 
TABLE 7, TABLE 8 and TABLE 9 show changes from baseline after twelve 
months of GH treatment in different arm pQCT parameters for both groups and 
they show a comparison between these groups.  
In arm pQCT measurements muscle area increased significantly in AGA with 
p = 0.046 (TABLE 7), in SGA with p = 0.043 (TABLE 8).  
Muscle area SDS increased significantly in AGA with p = 0.001 (TABLE 7), but 
not significantly in SGA with p = 0.060 (TABLE 8).  
Comparison of deltas between both groups were not significant (p = 0.61) 
(TABLE 9).  
All other pQCT parameters – fat area, fat area SDS, muscle density and various 
bone parameters – did not show significant changes in either of the groups. 
 
TABLE 10, TABLE 11 and TABLE 12 show different leg pQCT parameters and 
their changes from baseline after twelve months of GH treatment. 
In pQCT measurements of the leg muscle area increased significantly in SGA 
with p = 0.015 (TABLE 11), increase in AGA was not significant (TABLE 10). 
Fat area and muscle density did not change significantly in either of the groups 
(TABLE 10, TABLE 11). Cortical vBMD decreased significantly in AGA with 
p = 0.037 (TABLE 10), but not in SGA (TABLE 11). Significant increases in 
SGA were found in cortical CSA with p = 0.030, cortical thickness with p = 0.027 
and cortical content with p = 0.039 (TABLE 11). These parameters did not show 
significant increase in AGA (TABLE 10).  
No significant difference in the changes of the first year of GH and after twelve 
months of treatment was found between groups in arm or leg pQCT 
measurements (TABLE 9 and TABLE 12). 
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5 Discussion 
5.1 Discussion of results 
5.1.1 Initial position 
Children were selected at early childhood when seen by a pediatrician because 
of growth retardation. Inclusion criteria were a birth weight below 1500 g for 
term born and preterm born children and an insufficient catch-up growth with a 
height at start of treatment being -2 SDS or lower. Further distinctions between 
the AGA children (e.g. whether growth restraint was experienced before term or 
afterwards) was not possible since data were not available for all children. It 
would be good if all preterm born children had been examined by a pediatrician 
at their calculated term date. We divided the study group by birth criteria AGA 
and SGA and included only those children with pQCT data from start and after 
twelve months of GH-treatment. 
5.1.2 No significant differences between AGA and SGA 
Results of this study show no significant differences between AGA and SGA 
children in their auxological parameters at start of GH treatment. This has 
already been described in recent studies 5, 7, 6, 12. Ranke et al. investigated 
growth and development in 97 preschool children born AGA or SGA at a birth 
weight < 1500 g. Short AGA and SGA children at follow-up had smaller head 
circumferences and a higher rate of bronchopulmonary dysplasia 5. In a Dutch 
study on long-term height gain of very preterm born children, Finken et al. 
demonstrates a 20% prevalence of persistent short stature. Very preterm 
children with what Wit et al. called the ‘preterm growth restraint’ (PGR) with a 
height below -2 SDS at the age of 5 years both result in a median adult height 
of -2,5 SDS, irrespective of whether they were born SGA or AGA. The study 
states that preterm growth restraint prefigures long-term sequelae independent 
of the perinatal phase when the growth restraint happened, whether in utero, ex 
utero or both 7. Wit et al. thus recommend the usage of the term ‘preterm 
growth restraint’ (PGR) to indicate poor growth in the third trimester since this 
appears to be a more appropriate term for either preterm born AGA or term 
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born SGA with a low weight and/or length at term age 6. Saigal et al. examined 
154 ELBW survivors being born at a birth weight between 501-1000 g. No 
significant difference in mean heights and weights was found between ELBW 
adolescents who were born SGA or AGA 12. 
5.1.3 Growth restraint in AGA and SGA 
Data of this study on AGA and SGA children show low SDS for height, weight, 
height velocity and muscle mass and higher fat proportions before GH 
treatment in comparison to age- and sex-matched references. Fat area was 
lower than normal, but muscle SDS and weight SDS were much lower than fat 
SDS, leaving relatively more fat on the extremities of the children. This 
corresponds to clinical experience: the examiner is often astonished to feel 
more fatty tissue than expected on these very thin extremities. 
Euser et al. state in their review that preterm born children show a substantial 
growth failure in their early postnatal period. The majority shows catch-up 
growth until 2-3 years of age and in some cases until adolescence. In spite of 
this, most preterm born infants remain shorter and lighter than term-born infants 
during their growth period. An altered, often disadvantageous, body composition 
in adulthood with an increased fat-to-muscle ratio may be the result of 
disproportionate catch-up growth, though early catch-up growth is beneficial for 
neurodevelopmental outcome 10. 
Saigal et al. report on ELBW adolescents being 5.8 cm shorter and 5.8 kg 
lighter than term control participants in their study. ELBW children show a 
significantly greater catch-up in weight than in height with a higher increase in 
BMI over time in ELBW girls 12. 
5.1.4 GH treatment criteria and dosage 
The children in this cohort were receiving a relatively high GH dose up to 
55 µg/kg/d with similar doses in both groups. There are differing 
recommendations as to the optimal dosage as described below. The given dose 
was thought to be appropriate because it was between the low and high dose 
used by de Zegher et al. 11 and because the first years of treatment were 
thought to offer the highest chance of catch-up without wasting time titrating 
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upwards. This GH dose was reached in increments 4 weeks after starting 
treatment and then titrated according to IGF-1 levels and reduced if IGF-1 was 
above + 2 SDS. Reduction of the given GH dose was necessary in five children, 
four of the SGA group and one in the AGA group. In our institution SGA children 
are now usually started at 33 µg/kg/d and titrated to a maximum of 50 µg/kg/d if 
they are not responding. 
GH treatment of children with short stature who were born SGA is approved by 
the FDA (Food and Drug Administration) and EMEA (European Agency for the 
Evaluation of Medicinal Products). The FDA-approved indication (2001) for GH 
treatment in short SGA children is absent catch-up growth with a starting age of 
two years; the starting dose is 70 µg/kg/d. No references to height SDS at start 
nor to midparental height are given. The EMEA-approved indication (2003) for 
treating short SGA children with GH is for children at the age of four years with 
height SDS of -2.5, growth velocity for age below 0 SD and height SDS being 
more than 1 SD below their midparental height SDS. The allocated starting 
dose is 35 µg/kg/d 3. 
In Europe, a daily GH dose of 33 µg/kg has been recommended for short SGA 
children up to adult height starting at age 4-6 years. If height is below -3 SDS an 
initial higher dose of approximately 50 µg/kg/d has been recommended with a 
decrease to 33 µg/kg/d when short-term catch-up growth has been achieved 
and long-term growth to a normal adult height is likely 11, 28. A final dosage 
recommendation can still not be made today since we are lacking long-term 
follow-up of both SGA and AGA children into adulthood with regard to their 
health risk profile. The SGA and AGA children of this study show a similar 
increase in height SDS in the first year of GH treatment with little acceleration of 
bone maturation under GH treatment in either groups, as already described by 
Sas et al. in a 5-year randomized, double-blind, dose-response GH study on 
SGA children (0.033 vs. 0.067 mg/kg per day). The process of bone maturation 
seemed to be independent of the individually given dose and a lower dose was 
sufficient for reaching normal height. The increment in height SDS for 
chronological age was not related to GH secretion levels or baseline IGF-I 
levels. Only children who remained prepubertal during the study period showed 
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a significantly higher increase in height SDS for chronological age in the study 
group receiving 0.067 mg/kg per day vs. 0.033 mg/kg per day 29.  
Van Pareren et al. later reported about the same study group as Sas et al. 29 on 
the achievement of adult height in a randomized, double-blind dose-response 
trial on long-term GH therapy in children born SGA without persistent catch-up 
growth: normalization of adult height was independent of GH dose (0.033 vs. 
0.067 mg/kg per day). Adult height SDS was significantly higher in the treatment 
group than in untreated control subjects 28. 
Dahlgren et al. showed in a study on short SGA children treated with GH that 
the highest benefit was achieved when treatment started early before the 
pubertal growth spurt begins. A normalization of height before puberty is 
essential and this gain is maintained during puberty to final height. Starting age 
and the duration of GH treatment were found to be the most indicative 
predictors for height gain. Height velocity at start has no influence on GH 
response. Prepubertal height gain through GH treatment seems to be dose-
dependent, whereas no dose effect was found during puberty 30. These results 
agree with the results of Sas et al. 29. 
Jung et al. have shown in the OPTIMA study on prepubertal short children born 
SGA that an individualized GH dose treatment with 0.035 mg/kg/day is not 
inferior to a treatment with a fixed high dose of 0.067 mg/kg/day in twelve 
months of GH-treatment. Treatment dose was increased to the higher dose of 
0.067 mg/kg/day after three months in the individually adjusted GH dose group 
if the predicted change in height SDS was below 0.75, using the Cologne 
growth-prediction model. Height SDS difference of -0.24 (fixed high dose group 
– individually adjusted dose group) resulting in a height difference of only 1 cm 
between the groups after one year was statistically significant but not 
considered to be clinically meaningful. The chosen non-inferiority margin for 
height SDS difference between both groups was to be -0.5. Adjustment of GH 
dosage reduces costs and increases safety by reducing the potential risk of 
over-stimulating of the IGF-I system with the possible results of impaired 
glucose tolerance 31. 
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In a retrospective study on skeletal maturation under GH treatment Darendeliler 
et al. have shown a normal progression of delayed bone age with a mean 
progression of one year during the first year of treatment with considerable 
interindividual variation. Pre-pubertal children from the KIGS database (Pfizer 
International Growth Database) with idiopathic growth hormone deficiency, 
Turner syndrome, idiopathic short stature and short children born SGA were 
included in the study. Bone age was assessed according to the method of 
Greulich and Pyle at baseline and after one year of therapy. No consistent 
effect of the dosage of GH on the progression of bone age was found 32. 
Arends et al. reported in a Dutch study on pre-pubertal short children born SGA 
on the effects of GH treatment (0.033 mg/kg/d) vs. no treatment on bone 
maturation and its relation to changes in height during three years of treatment. 
Spontaneous catch-up of bone age without GH treatment was about one year, 
whereas under GH mean catch-up of BA was up to 1.6 years. Under GH 
treatment a normalization of height with a proportionally increase in bone 
maturation to height gain can be shown. The reduced BMD and bone 
maturation in short SGA children normalizes under GH treatment with a 
significantly increase during the first two years of GH-treatment. A good 
predictor for 3-year height gain seems to be the ratio of ∆ BA (bone age)/∆ CA 
(chronological age). Height gain of severely short children with height SDS at or 
below -3 at start of GH treatment was not dependent on the given GH dose 
(0.033 vs. 0.067 mg/kg per day) and an early start of GH treatment is 
recommended 33. 
Martin et al. found a catch-up of bone age in SGA children of 1.4 years after 
one year of GH treatment with a treatment dose of 49.8±13.04 µg/kg/d (mean ± 
SD) 34. 
Labarta et al. reported in a retrospective study on untreated children born SGA 
that the onset of puberty occurs at a normal age but relatively early for body 
height. Untreated children born SGA appear to generally have a lower pubertal 
growth spurt than controls whilst the tempo of puberty is similar 35. 
Ranke et al. found the levels of IGF-1 and IGFBP-3 to be a useful indicator for 
GH sensitivity during initial GH dosage step-up in GH-treated short SGA 
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children and GH-deficient children 36. These parameters were measured 
throughout this study; they were low at start of treatment and showed a similar 
increase in both groups (see TABLE 4). 
5.1.5 Changes in body composition under growth hormone treatment 
Muscle area changed significantly in both groups in the first year under GH. 
Only in leg pQCT measurements of the AGA group was no significant change of 
muscle area found after the first year. 
No significant change of muscle density under GH treatment was found in this 
study, which is the first study to look at this parameter. This, together with the 
fact that the increase in muscle tissue is accompanied by an increase in muscle 
strength, indicates that the increase in muscle strength and the increase in 
muscle area are due to an increase in functional muscle tissue 27. The increase 
in muscle strength under GH suggests that the increase in muscle area is 
mainly functional muscle and not just the water accumulation that GH is also 
known to induce. The fact that the muscle density does not change also 
supports this – although this cannot be stated for sure since it is not known how 
sensitive pQCT is to muscle density changes through water accumulation. 
Best correlations to changes in muscle area under GH treatment were observed 
with changes in Strength Strain Index (SSI), polar moment of inertia, cortical 
cross-sectional area and cortical content in arm and leg pQCT-measurements, 
as well as in changes in bone mass in DXA-measurements and maximal 
isometric grip force of the non-dominant hand. 
SSI is a pQCT parameter for bone strength and sensitive to changes of bone 
mineralization. SSI is derived from the polar moment of inertia and the section 
modulus, which are mechanical parameters for describing the strength of 
elongated structures 23. The pQCT findings in this study with regard to the 
correlations between bone strength parameters and muscle area are similar to 
those of Schweizer et al. in a pQCT study on GH-deficient and SGA children 37. 
The data of this study display a non-significant decrease of cortical vBMD 
during the first year of GH therapy in both groups for arm pQCT measurements, 
being significant for the leg pQCT measurements in the AGA group with 
p < 0.05. Schweizer et al. described an initial decrease of cortical vBMD in GH-
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deficient children under GH replacement therapy caused by early bone 
remodeling 27. 
5.1.6 Body composition in preterm born children with growth restraint 
and further risks 
Leger et al. state that long-term GH treatment in short SGA children improves 
growth velocity and increases muscle cross-sectional area. Adipose tissue 
decreases during the first year of treatment followed by a slight increase during 
the second and third year. The effects of the three years of GH treatment can 
still be demonstrated one year after stopping treatment 38. 
Schweizer et al. show in a pQCT study on body composition of short SGA 
children that a subgroup of children born SGA has deficiencies in muscle-mass, 
muscle-strength and bone development 39. 
Untreated VLBW boys (birth weight < 1500 g) have been studied by Ericson et 
al. at the age of 19 years with regard to body composition and further sequelae. 
The young men were shorter and lighter, had a lower BMI than controls and 
showed a reduction in muscular strength and physical working capacity. A 
higher rate of visual and hearing impairments, an increased risk for cerebral 
palsy and other mental impairments, lower intelligent test scores and shorter 
schooling were also found 13. 
Saigal et al. studied ELBW children (birth weight between 501 to 1000 g) at 
adolescence. They showed significantly lower growth attainment on height, 
weight and head circumference; a higher prevalence of functional limitations 
and more use of health care and educational resources than term controls 12. 
Rogers et al. compared unimpaired ELBW adolescents being born at a birth 
weight below 800 g with term-born adolescents at the age of 17 years. ELBW 
adolescents showed significant differences in motor performance, flexibility and 
aerobic capacity than term-born controls. These differences can be related to 
effects of premature birth on the motor system and to a rather inactive lifestyle 
of ELBW survivors with potential implications for later health problems 14. 
A study on preterm birth and later insulin resistance by Finken et al. showed a 
weak association of rapid infancy weight gain of preterm born children until 
three months post-term with higher insulin levels at 19 years of age. Adult 
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obesity is a strong predictor for higher insulin and C-peptide levels, as well as 
higher HOMA-IR (homeostatic model assessment for insulin resistance index) 
with a larger effect on these parameters shown in obese adults being born at a 
lower birth weight 15. 
Rapid weight gain in small babies may lead to an imbalance in body 
composition with high fat mass but low muscle mass, whereas an increase in 
body weight within the first year is associated with a reduced risk of coronary 
events as adults. An increase in the SDS for BMI after two years of age has 
been found by Barker et al. to be a stronger predictor of later coronary events 
than BMI obtained at any other age 16. 
Hack et al. display in a prospective study on growth of VLBW infants up to 20 
years of age that VLBW females catch-up more in weight than in height, 
whereas VLBW males remain shorter and lighter than control subjects. There is 
concern about children, esp. VLBW females, who catch-up rapidly to have a 
higher risk for developing metabolic syndrome in adulthood 17. 
Singhal et al. showed in a study on body composition of adolescents an 
association of a higher birth weight with greater fat-free mass, but not with 
greater fat mass. Poor fetal growth, which is measured in a low birth weight, is 
suggested to lead to a programming of a smaller proportion of lean mass in 
further life. The association of birth weight with lean body mass is independent 
of height. Low birth weight may program a smaller proportion of lean mass and 
adversely affect later metabolic status with impaired insulin sensitivity and 
thereby increase the risk for developing cardiovascular diseases 18. 
Some untreated preterm born children with growth retardation are thus at risk of 
developing metabolic disorders such as deranged glucose-tolerance and 
diabetes and furthermore coronary insufficiency 15, 16, 17, 18. Whether the GH-
induced increase in muscle mass and decrease in fat mass in our study later 
leads to a better metabolic status is as yet unknown. In the children of this study 
a clear increase of insulin levels within the normal range was observed (TABLE 
4). Martin et al. have shown that in the short term increase in muscle mass and 
decrease in fat mass was inversely related to increase in insulin resistance in 
short children born SGA undergoing GH treatment 40. Long-term monitoring is 
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necessary to assess whether the effects of growth hormone on fat, muscle and 
bone of preterm SGA and AGA children has long-term benefits (or risks) for 
their metabolic health.  
5.1.7 Adverse effects of GH treatment 
None of the known side effects of GH were observed in the children of this 
study. Possible long-term adverse effects of GH therapy are not yet fully known.  
A known effect of GH therapy is the above-mentioned reversible decrease of 
insulin sensitivity 40. In our patients we saw a clear increase of insulin levels, 
within the normal range (see TABLE 4).  
5.1.8 Height velocity 
The inclusion criteria dictate that height velocity was < 0 SDS at the time the 
decision to start treatment was taken (which was about 2-5 months before GH 
start). Yet TABLE 4 shows that some children had normal height velocity at the 
time of GH start. The height velocity given in TABLE 4 represents the height 
velocity between the last measurement before GH start and the measurement 
at GH start. This seeming acceleration of growth after the decision to start GH 
in some children could either be due to imprecision (short time span between 
the measurements, too low measurement at the time of making the decision 
and/or too high measurement at the time of GH start) – or perhaps even 
because the children experience a psychological boost due to either them or 
their parents, or both, feeling relieved that something is going to be done about 
the short stature. This phenomenon would perhaps deserve further study in a 
metaanalysis of a large number of growth hormone studies. From our previous 
studies we would expect slightly lower height velocities of about 5.5±1 cm/year 
(-0.55±1 SDS) at GH start in short children born SGA 40. 
5.2 Weaknesses of this study 
The weaknesses of this study can be seen in small study groups without 
randomized control groups receiving placebo or no treatment. The latter would 
have been an ethically difficult issue in these children. Using no treatment may 
offer a psychological advantage (no injection stress – which can be very high in 
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VLBW children) or disadvantage (“no one is doing anything about my short 
stature”), and giving placebo injections was not acceptable for many parents, 
whose VLBW children often have had more or less traumatic hospital 
experiences in the past. This is why we decided to compare the VLBW children 
with the already well-described SGA children. It would have been useful to have 
two measurements at different times before GH start to be able to quantify the 
effect of GH more precisely in each group, but again, this would have been an 
extra burden on the children and their families. However, these potential 
drawbacks do not affect the main outcome of this study i.e. the difference 
between the groups.  
Unfortunately an initially planned intraindividual comparison of leg pQCT 
measurements to jumping performances on a Leonardo Jumping Platform was 
not possible, because the PC with the database of jumping examinations 
resetted the actual date of examinations to the basic set date of the PC and this 
error was not noticed before the examinations were completed. 
5.3 Recommendation 
On the basis of this study we can make some methodical recommendations for 
further pQCT studies. pQCT measurements in this study show better results in 
leg measurements than in arm measurements. Even slight movements during 
the measuring process reduce the quality. The courses of total area (leg), 
muscle area (leg), total cross-sectional area (tibia) and cortical cross-sectional 
area (tibia) to age (y) show smoother increments than the equivalent 
measurements of the arm, whereas the courses in fat area measurements in 
arms and legs do not show any uniformity (see appendix). 
Unfortunately, 40 pQCT measurements of the arm and 12 pQCT measurements 
of the calf showed poor quality due to minor movements, with examples in the 
appendix. Two pQCT measurements of the arm at the beginning of GH 
treatment had to be excluded (see appendix). 
In order to achieve better results it is recommendable to perform pQCT 
measurements in children of the calf rather than of the arm because the calf 
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measurements are much less prone to movement artifacts. However, reference 
data for pQCT measurements of the calf in children have yet to be published.  
6 Conclusion 
In conclusion, this study did not show significant differences of prepubertal 
auxological parameters in preterm short VLBW children born AGA and SGA. 
The AGA group showed a similar or stronger response to GH treatment 
compared to the SGA group in terms of growth, muscle and fat changes. The 
positive response and tolerability of growth hormone warrants a discussion 
about the benefits and risks of growth hormone treatment in both groups 
instead of excluding a-priori those who experienced the preterm growth restraint 
outside the uterus i.e. the preterm VLBW AGA. These results reveal the 
arbitrary nature of using the criterion “SGA” for eligibility to growth hormone 
treatment in children born with a birth weight below 1500 g. 
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7.1 Tables 
TABLE 4: Baseline values and changes after 12 months of GH treatment for auxology, 
height velocity (HV), maximum isometric grip force (MIFG), BIA impedance and 
resistance, IGFs and skinfolds for group AGA  
 
AGA (N=27, 12 females) 
Time of GH (mo) 0 0 12 12 
∆ 0 to 
12 
∆ 0 to 
12 
0 vs. 12 
mo 
  
    
Paired t-test analysis 
Auxological 
characteristics Mean SD 
Mea
n SD Mean Std Err p Value 
Height (cm) 106 12 116 12 9.8 0.32 <.0001 
Height (SDS) -3.3 0.84 -2.4 0.80 0.92 0.070 <.0001 
Weight (kg) 16 5.82 20 7.8 3.7 0.43 <.0001 
Weight (SDS) -2.6 0.82 -2.04 0.72 0.52 0.13 0.0003 
HV (cm/year) 6.2 1.1 9.6 1.3 3.4 0.32 <.0001 
HV (SDS) -0.0015 1.03 4.2 1.7 4.2 0.44 <.0001 
Age (years) 6.9 2.3 8.0 2.3 1.0 0.016 <.0001 
Bone age (years) 5.8 2.5 6.8 2.4 1.1 0.19 0.0001 
MIGF (N) non-
dominant 62 37 81 43 23 4.9 0.0002 
MIGF (SDS) non-
dominant -0.59 1.2 -0.31 1.4 0.26 0.21 0.23 
Resistance R (Ohm) 810 88 695 86 -105 20 <.0001 
Reactance Xc (Ohm) 71 8.5 66 5.8 -3.4 1.6 0.048 
IGF-1 (ng/mL) 95 41 214 112 122 19 <.0001 
IGF-1 (SDS) -1.9 1.1 0.43 1.3 2.3 0.27 <.0001 
IGFBP-3 (ng/mL) 2461 590 3740 870 1313 150 <.0001 
IGFBP-3 (SDS) -1.7 0.98 -0.08 0.91 1.6 0.19 <.0001 
Skinfold triceps (mm) 7.4 2.5 6.1 4.0 -1.5 0.43 0.0029 
Insulin (pmol/L) 28 31 42 56 -3.7 9.4 0.70 
C-peptide (pmol/L) 271 301 263 163 -72 93 0.45 
Glucose (mg/dL) 80 12 75 10.0 -6.5 4.9 0.20 
Plasma glucose 
(mmol/L) 4.5 0.68 4.2 0.55 -0.3595 0.27 0.20 
HOMA2-IR 0.6 0.56 0.56 0.32 -0.11 0.16 0.50 
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TABLE 5: Baseline values and changes after 12 months of GH treatment for auxology, 
height velocity (HV), maximum isometric grip force (MIFG), BIA impedance and 
resistance, IGFs and skinfolds for group SGA 
 
SGA (N=17, 6 females) 
Time of GH (mo) 0 0 12 12 
∆ 0 to 
12 
∆ 0 to 
12 
0 vs. 12 
mo 
  
    
Paired t-test analysis 
Auxological 
characteristics Mean SD Mean SD Mean Std Err p Value 
Height (cm) 106 14 115 13 9.3 0.59 <.0001 
Height (SDS) -3.3 0.73 -2.6 0.87 0.71 0.14 <.0001 
Weight (kg) 15 4.1 18 4.6 3.2 0.22 <.0001 
Weight (SDS) -2.9 0.55 -2.3 0.63 0.53 0.091 <.0001 
HV (cm/year) 5.7 1.7 8.8 1.8 3.1 0.44 <.0001 
HV (SDS) -0.18 1.7 3.3 1.9 3.5 0.57 <.0001 
Age (years) 7.1 3.1 8.2 3.1 1.1 0.035 <.0001 
Bone age (years) 4.3 3.8 5.3 3.5 0.97 0.45 0.098 
MIGF (N) non-
dominant 49 32 82 47 39 9.8 0.0018 
MIGF (SDS) non-
dominant -1.1 1.6 -0.56 1.1 0.59 0.56 0.31 
Resistance R (Ohm) 829 88 714 75 -92 16 0.0001 
Reactance Xc (Ohm) 75 11 70 8.9 -4.3 2.8 0.16 
IGF-1 (ng/mL) 106 60 233 130 133 21 <.0001 
IGF-1 (SDS) -1.9 1.6 0.47 1.4 2.5 0.35 <.0001 
IGFBP-3 (ng/mL) 2903 880 3957 884 1137 185 <.0001 
IGFBP-3 (SDS) -1.02 1.2 0.14 0.69 1.3 0.27 0.0002 
Skinfold triceps (mm) 7.5 2.1 5.9 2.1 -2.2 0.35 <.0001 
Insulin (pmol/L) 22 11 41 24 13 8.8 0.18 
C-peptide (pmol/L) 169 116 345 159 151 94 0.16 
Glucose (mg/dL) 80 7.7 79 10 -3.4 4.7 0.49 
Plasma glucose 
(mmol/L) 4.4 0.43 4.4 0.53 -0.19 0.26 0.49 
HOMA2-IR 0.48 0.15 0.75 0.42 0.18 0.16 0.31 
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TABLE 6: Comparison of p values in unpaired two tailed t-test of group AGA and SGA for 
baseline values and changes after 12 months of GH treatment for auxology, height 
velocity (HV), maximum isometric grip force (MIFG), BIA impedance and resistance, IGFs 
and skinfolds 
 
AGA vs. SGA 
Time of GH (mo) 0 12 ∆ 0 to 12 
  Unpaired two tailed t-test 
Auxological characteristics p Value p Value p Value 
Height (cm) 0.96 0.85 0.43 
Height (SDS) 1.0 0.43 0.19 
Weight (kg) 0.60 0.52 0.39 
Weight (SDS) 0.14 0.15 0.98 
HV (cm/year) 0.33 0.14 0.55 
HV (SDS) 0.70 0.13 0.36 
Age (years) 0.82 0.79 0.34 
Bone age (years) 0.47 0.41 0.83 
MIGF (N) non-dominant 0.25 0.95 0.15 
MIGF (SDS) non-dominant 0.28 0.54 0.59 
Resistance R (Ohm) 0.54 0.52 0.60 
Reactance Xc (Ohm) 0.18 0.22 0.81 
IGF-1 (ng/mL) 0.50 0.62 0.70 
IGF-1 (SDS) 0.92 0.93 0.67 
IGFBP-3 (ng/mL) 0.09 0.44 0.46 
IGFBP-3 (SDS) 0.081 0.38 0.37 
Skinfold triceps (mm) 0.86 0.84 0.21 
Insulin (pmol/L) 0.38 0.97 0.20 
C-peptide (pmol/L) 0.16 0.16 0.11 
Glucose (mg/dL) 0.86 0.22 0.65 
Plasma glucose (mmol/L) 0.86 0.22 0.65 
HOMA2-IR 0.35 0.18 0.22 
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TABLE 7: Changes from baseline in arm pQCT after 12 months of GH treatment for group 
AGA 
  AGA (N=25, 10 females) 
Time of GH (mo) 0 0 12 12 
∆ 0 to 
12 
∆ 0 
to 12 
0 vs. 
12 mo 
  
    
Paired t-test analysis 
Arm pQCT Mean SD Mean SD Mean 
Std 
Err 
p 
Value 
Muscle area (mm²) 1177 323 1400 316 223 105 0.046 
Muscle area (SDS, 
formula) -2.2 0.91 -0.73 1.1 1.5 0.35 0.0010 
Muscle area (height-SDS, 
formula) -2.2 0.91 -0.81 1.3 1.5 0.48 0.011 
Muscle area (height-age-
SDS, formula) -1.1 1.2 0.17 1.5 1.5 0.50 0.012 
Fat area (mm²) 527 201 440 357 -87 75 0.26 
Fat area (SDS, formula) -1.1 0.94 -1.8 1.1 -0.77 0.37 0.054 
Fat area (height-SDS, 
formula) -1.4 1.5 -2.6 2.03 -1.4 0.71 0.082 
Fat area (height-age-SDS, 
formula) -1.10 1.4 -1.9 1.5 -1.3 0.51 0.030 
Total vBMD (mg/cm³) 319 142 345 107 26 41 0.53 
Cortical vBMD (mg/cm³) 944 63 937 49 -6.8 18 0.71 
Total CSA (mm²) 75 21 80 24 4.9 6.1 0.42 
Total CSA (SDS, formula) -0.24 1.3 0.13 1.6 0.37 0.61 0.56 
Total CSA (height-SDS, 
table) 0.19 2.6 0.69 1.8 0.47 1.0 0.65 
Total CSA (height-age-
SDS, formula) 0.11 1.4 0.54 1.5 0.52 0.72 0.48 
Cortical CSA (mm²) 25 11 29 9 4 3 0.22 
Cortical CSA (SDS, 
formula) -1.3 0.56 -1.0 1.0 0.31 0.28 0.29 
Cortical CSA (height-SDS, 
table) 0.51 1.5 0.21 1.2 -0.052 0.55 0.93 
Cortical CSA (height-age 
SDS, formula) -0.36 0.84 -0.28 0.74 0.14 0.38 0.71 
Cortical thickness (mm) 0.90 0.39 1.0 0.29 0.12 0.12 0.32 
Cortical thickness (SDS, 
formula) -1.5 0.90 -1.2 1.2 0.24 0.39 0.56 
Cortical thickness (height-
age-SDS, formula) -0.73 1.0 -0.71 0.81 0.062 0.44 0.89 
Cortical content (mg/mm) 24 12 27 9.1 3.6 3.5 0.32 
Cortical content (SDS, 
formula) -0.91 1.0 -0.92 1.3 -0.015 0.38 0.97 
Cortical content (height-
age-SDS, formula) 0.89 0.97 0.35 1.2 -0.46 0.46 0.34 
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Muscle density (mg/mL) 74 7.2 77 4.0 2.9 1.7 0.099 
Bone mineral content 
(SDS, table) -2.3 0.97 -1.7 1.4 0.59 0.47 0.24 
Bone mineral content 
(height-SDS, table) -0.82 0.99 -0.41 0.84 0.49 0.39 0.23 
Total density (SDS, table) 0.17 1.7 -0.10 1.1 -0.42 0.64 0.53 
Total density (height-SDS, 
table) 1.8 1.3 1.2 1.3 -0.73 0.47 0.15 
Cortical density (SDS, 
formula) -0.18 1.1 -0.55 0.95 -0.26 0.31 0.41 
Cortical density (height-
SDS, table) 2.1 1.2 0.42 0.80 -1.7 0.46 0.0028 
Cortical density (height-
age-SDS, formula) 0.60 1.1 -0.13 0.72 -0.63 0.29 0.0555 
SSI (mm³) 73 32 84 33 11 10 0.28 
SSI (SDS, formula) -1.1 0.45 -1.0 1.0 0.11 0.29 0.71 
SSI (height-SDS, table) 0.31 1.5 -0.070 1.6 -0.17 0.47 0.72 
SSI (height-age-SDS, 
formula) -0.087 0.66 -0.20 0.95 0.062 0.38 0.87 
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TABLE 8: Changes from baseline in arm pQCT after 12 months of GH treatment for group 
SGA 
  SGA (N=16, 6 females) 
Time of GH (mo) 0 0 12 12 
∆ 0 
to 12 
∆ 0 
to 12 
0 vs. 
12 mo 
          
Paired t-test 
analysis 
Arm pQCT Mean SD Mean SD Mean  
Std 
Err  
p 
Value 
Muscle area (mm²) 1067 261 1311 365 243 108 0.043 
Muscle area (SDS, formula) -3.2 1.9 -1.2 1.5 2.0 0.92 0.060 
Muscle area (height-SDS, 
formula) -3.1 1.9 -1.2 1.6 0.97 0.87 0.30 
Muscle area (height-age-
SDS, formula) -2.3 2.2 -0.58 1.9 1.9 1.04 0.10 
Fat area (mm²) 525 195 408 210 -117 65 0.093 
Fat area (SDS, formula) -0.62 1.8 -1.7 0.74 -1.1 0.66 0.12 
Fat area (height-SDS, 
formula) -1.1 2.1 -2.4 1.3 -1.5 1.00 0.18 
Fat area (height-age-SDS, 
formula) -1.2 1.7 -1.7 0.66 -0.69 0.58 0.28 
Total vBMD (mg/cm³) 342 132 358 142 16 62 0.80 
Cortical vBMD (mg/cm³) 968 68 954 54 -14 21 0.52 
Total CSA (mm²) 71 16 86 16 16 7.6 0.061 
Total CSA (SDS, formula) -0.64 0.75 0.70 1.3 1.3 0.72 0.099 
Total CSA (height-SDS, 
table) 0.59 2.1 1.59 1.9 0.88 1.2 0.47 
Total CSA (height-age-
SDS, formula) -0.16 1.0 0.95 1.8 1.3 0.70 0.10 
Cortical CSA (mm²) 24 9 30 11 5.3 3.0 0.10 
Cortical CSA (SDS, 
formula) -1.4 0.83 -0.92 1.3 0.50 0.52 0.36 
Cortical CSA (height-SDS, 
table) -0.025 2.7 -0.023 1.4 0.050 1.2 0.97 
Cortical CSA (height-age 
SDS, formula) -0.79 0.75 -0.29 0.85 0.54 0.31 0.12 
Cortical thickness (mm) 0.91 0.33 1.1 0.40 0.14 0.15 0.37 
Cortical thickness (SDS, 
formula) -1.6 1.0 -1.5 1.5 0.093 0.66 0.89 
Cortical thickness (height-
age-SDS, formula) -1.1 0.95 -0.90 1.03 0.26 0.54 0.65 
Cortical content (mg/mm) 24 10 29 11 4.7 3.2 0.17 
Cortical content (SDS, 
formula) -0.57 1.2 -0.55 1.7 0.019 0.77 0.98 
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Cortical content (height-
age-SDS, formula) 0.47 1.13 0.65 1.3 0.032 0.62 0.96 
Muscle density (mg/mL) 76 3.7 78 4.1 2.1 1.3 0.13 
Bone mineral content (SDS, 
table) -2.0 2.1 -0.83 1.2 0.92 1.03 0.40 
Bone mineral content 
(height-SDS, table) -0.82 0.96 -0.13 0.66 0.72 0.38 0.10 
Total density (SDS, table) 0.74 2.0 0.23 1.8 -0.68 0.88 0.46 
Total density (height-SDS, 
table) 2.0 2.1 1.5 2.2 -0.76 0.97 0.46 
Cortical density (SDS, 
formula) 0.17 1.4 -0.31 1.3 -0.52 0.69 0.47 
Cortical density (height-
SDS, table) 4.6 5.5 1.7 2.4 -3.9 2.1 0.11 
Cortical density (height-
age-SDS, formula) 1.02 1.4 0.30 1.00 -0.65 0.59 0.31 
SSI (mm³) 69 29 86 30 17 7.9 0.057 
SSI (SDS, formula) -1.2 0.83 -0.69 1.3 0.48 0.44 0.30 
SSI (height-SDS, table) -0.38 2.2 -0.26 0.95 0.18 0.72 0.81 
SSI (height-age-SDS, 
formula) -0.46 0.67 -0.033 0.79 0.44 0.32 0.21 
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TABLE 9: Comparison of p values for changes from baseline in arm pQCT after 12 
months of GH treatment 
   AGA vs. SGA  
Time of GH (mo) 0 12 ∆ 0 to 12 
  Unpaired two tailed t-test 
Arm pQCT p Value p Value p Value 
Muscle area (mm²) 0.20 0.48 0.89 
Muscle area (SDS, formula) 0.13 0.48 0.61 
Muscle area (height-SDS, formula) 0.13 0.48 0.60 
Muscle area (height-age-SDS, formula) 0.084 0.31 0.71 
Fat area (mm²) 1.00 0.74 0.76 
Fat area (SDS, formula) 0.44 0.84 0.65 
Fat area (height-SDS, formula) 0.61 0.66 0.92 
Fat area (height-age-SDS, formula) 0.87 0.56 0.44 
Total vBMD (mg/cm³) 0.71 0.88 0.90 
Cortical vBMD (mg/cm³) 0.46 0.31 0.79 
Total CSA (mm²) 0.48 0.53 0.28 
Total CSA (SDS, formula) 0.30 0.41 0.32 
Total CSA (height-SDS, table) 0.66 0.23 0.79 
Total CSA (height-age-SDS, formula) 0.54 0.53 0.45 
Cortical CSA (mm²) 0.80 0.87 0.79 
Cortical CSA (SDS, formula) 0.21 0.80 0.76 
Cortical CSA (height-SDS, table) 0.52 0.65 0.94 
Cortical CSA (height-age SDS, formula) 0.15 0.98 0.43 
Cortical thickness (mm) 0.99 0.87 0.92 
Cortical thickness (SDS, formula) 0.36 0.59 0.86 
Cortical thickness (height-age-SDS, 
formula) 0.31 0.62 0.78 
Cortical content (mg/mm) 0.91 0.78 0.82 
Cortical content (SDS, formula) 0.77 0.59 0.97 
Cortical content (height-age-SDS, 
formula) 0.30 0.56 0.53 
Muscle density (mg/mL) 0.19 0.32 0.70 
Bone mineral content (SDS, table) 0.59 0.083 0.78 
Bone mineral content (height-SDS, table) 0.98 0.34 0.67 
Total density (SDS, table) 0.42 0.60 0.81 
Total density (height-SDS, table) 0.74 0.66 0.98 
Cortical density (SDS, formula) 0.45 0.60 0.74 
Cortical density (height-SDS, table) 0.12 0.10 0.35 
Cortical density (height-age-SDS, 
formula) 0.38 0.23 0.97 
SSI (mm³) 0.62 0.93 0.68 
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SSI (SDS, formula) 0.45 0.35 0.49 
SSI (height-SDS, table) 0.33 0.69 0.68 
SSI (height-age-SDS, formula) 0.15 0.62 0.46 
 
TABLE 10: Changes from baseline in leg pQCT after 12 months of GH treatment for group 
AGA 
  AGA (n = 22, 10 females) 
Time of GH (mo) 0 0 12 12 
∆ 0 
to 12 
∆ 0 to 
12 
0 vs. 
12 mo 
          
Paired t-test 
analysis 
Leg pQCT Mean SD Mean SD Mean  
Std 
Err p Value 
Muscle area (mm²) 2435 623 2846 926 411 207 0.065 
Fat area (mm²) 894 414 666 475 -619 588 0.10 
Total vBMD (mg/cm³) 507 146 501 96 -6.0 39 0.88 
Cortical vBMD (mg/cm³) 1030 56 999 35 -31 13 0.037 
Total CSA (mm²) 213 71 235 66 22 15 0.17 
Cortical CSA (mm²) 102 33 118 41 16 11 0.16 
Cortical thickness (mm) 2.3 0.65 2.5 0.64 0.23 0.22 0.33 
Cortical content (mg/mm) 105 43 119 51 14 12 0.27 
Muscle density (mg/mL) 78 4.0 78 2.9 0.41 1.3 0.76 
SSI (mm³) 463 198 547 250 83 53 0.14 
 
TABLE 11: Changes from baseline in leg pQCT after 12 months of GH treatment for group 
SGA 
  SGA (n = 15, 4 females) 
Time of GH (mo) 0 0 12 12 
∆ 0 
to 12 
∆ 0 
to 12 
0 vs. 
12 mo 
          
Paired t-test 
analysis 
Leg pQCT Mean SD Mean SD Mean  
Std 
Err  
p 
Value 
Muscle area (mm²) 2005 467 2526 583 521 188 0.015 
Fat area (mm²) 832 249 700 403 -132 87 0.15 
Total vBMD (mg/cm³) 449 147 522 119 73 44 0.12 
Cortical vBMD (mg/cm³) 997 60 1001 38 3.6 15 0.81 
Total CSA (mm²) 204 54 209 47 5.2 18 0.78 
Cortical CSA (mm²) 89 33 108 36 19 7.8 0.030 
Cortical thickness (mm) 2.1 0.71 2.5 0.70 0.45 0.18 0.027 
Cortical content (mg/mm) 90 46 109 46 19 8.1 0.039 
Muscle density (mg/mL) 79 1.7 79 2.2 -0.21 0.86 0.81 
SSI (mm³) 398 192 463 195 64 46 0.19 
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TABLE 12: Comparison of p values for changes from baseline in leg pQCT after 12 
months of GH treatment 
  AGA vs. SGA 
Time of GH (mo) 0 12 ∆ 0 to 12 
  Unpaired two tailed t-test 
Leg pQCT p Value 
p 
Value p Value 
Muscle area (mm²) 0.93 0.26 0.70 
Fat area (mm²) 0.59 0.83 0.95 
Total vBMD (mg/cm³) 0.44 0.49 0.19 
Cortical vBMD (mg/cm³) 0.26 0.84 0.10 
Total CSA (mm²) 0.79 0.16 0.48 
Cortical CSA (mm²) 0.65 0.43 0.84 
Cortical thickness (mm) 0.56 0.85 0.45 
Cortical content (mg/mm) 0.58 0.46 0.75 
Muscle density (mg/mL) 0.23 0.65 0.70 
SSI (mm³) 0.67 0.24 0.79 
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TABLE 13: Correlation to pQCT muscle area (arm/leg) of various pQCT parameters, MIGF 
and DXA bone mass with R², N, p by time from GH start; 0 months 
Time from GH start (mo) 0 
Correlation to muscle area (mm²) of R² N 
p Value 
MA 
Total CSA (mm²) to MA (mm²) (arm) 0.54 40 <0.0001 
Cortical CSA radius (mm²) to MA (mm²) (arm) 0.61 38 <0.0001 
Cortical thickness (mm) to MA (mm²) (arm) 0.36 38 <0.0001 
Total vBMD (mg/cm³) to MA (mm²) (arm) 0.15 38 0.018 
Cortical content radius (mg/mm) to MA (mm²) (arm) 0.59 38 <0.0001 
Cortical vBMD (mg/cm³) to MA (mm²) (arm) 0.24 38 0.0017 
Polar moment of inertia radius (mm⁴) to MA (mm²) (arm) 0.76 38 <0.0001 
SSI radius (mm³) to MA (mm²) (arm) 0.78 38 <0.0001 
Fat area (mm²) to MA (mm²) (arm) 0.0058 41 0.64 
Muscle density (mg/mL) to MA (mm²) (arm) 0.0048 41 0.67 
DXA bone mass (g) to MA (mm²) (arm) 0.66 13 0.00070 
DXA: Bone mineral density (g/cm²) to MA (mm²) (arm) 0.0041 13 0.84 
MIGF of non-dominant hand (N) to MA (mm²) (arm) 0.56 36 <0.0001 
Leg: Total CSA tibia (mm²) to MA (mm²) (leg) 0.49 32 <0.0001 
Leg: Cortical CSA tibia (mm²) to MA (mm²) (leg) 0.67 35 <0.0001 
Leg: Cortical thickness tibia (mm) to MA (mm²) (leg) 0.33 35 0.00030 
Leg: Total vBMD (mg/cm³) to MA (mm²) (leg) 0.064 32 0.16 
Leg: Cortical content tibia (mg/mm) to MA (mm²) (leg)  0.64 35 <0.0001 
Leg: Cortical vBMD tibia (mg/cm³) to MA (mm²) (leg) 0.10 32 0.072 
Leg: Polar moment of inertia tibia (mm⁴) to MA (mm²) 
(leg) 0.64 35 <0.0001 
Leg: SSI tibia (mm³) to MA (mm²) (leg) 0.73 35 <0.0001 
Leg: Fat area (mm²) to MA (mm²) (leg) 0.15 37 0.018 
Leg: Muscle density (mg/mL) to MA (mm²) (leg) 0.000027 36 0.98 
MIGF of non-dominant hand (N) to MA (mm²) (leg) 0.50 31 <0.0001 
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TABLE 14: Correlation to pQCT muscle area (arm/leg) of various pQCT parameters, MIGF 
and DXA bone mass with R², N, p by time from GH start; 6 months 
Time from GH start (mo) 6 
Correlation to muscle area (mm²) of R² N 
p Value 
MA 
Total CSA (mm²) to MA (mm²) (arm) 0.44 32 <0.0001 
Cortical CSA radius (mm²) to MA (mm²) (arm) 0.76 32 <0.0001 
Cortical thickness (mm) to MA (mm²) (arm) 0.56 32 <0.0001 
Total vBMD (mg/cm³) to MA (mm²) (arm) 0.36 32 0.00030 
Cortical content radius (mg/mm) to MA (mm²) (arm) 0.74 32 <0.0001 
Cortical vBMD (mg/cm³) to MA (mm²) (arm) 0.39 32 0.00010 
Polar moment of inertia radius (mm⁴) to MA (mm²) (arm) 0.67 32 <0.0001 
SSI radius (mm³) to MA (mm²) (arm) 0.77 32 <0.0001 
Fat area (mm²) to MA (mm²) (arm) 0.0032 32 0.76 
Muscle density (mg/mL) to MA (mm²) (arm) 0.043 32 0.26 
DXA bone mass (g) to MA (mm²) (arm) 0.53 8 0.041 
DXA: Bone mineral density (g/cm²) to MA (mm²) (arm) 0.36 8 0.11 
MIGF of non-dominant hand (N) to MA (mm²) (arm) 0.65 29 <0.0001 
Leg: Total CSA tibia (mm²) to MA (mm²) (leg) 0.53 30 <0.0001 
Leg: Cortical CSA tibia (mm²) to MA (mm²) (leg) 0.57 28 <0.0001 
Leg: Cortical thickness tibia (mm) to MA (mm²) (leg) 0.48 28 <0.0001 
Leg: Total vBMD (mg/cm³) to MA (mm²) (leg) 0.216 30 0.0097 
Leg: Cortical content tibia (mg/mm) to MA (mm²) (leg)  0.57 28 <0.0001 
Leg: Cortical vBMD tibia (mg/cm³) to MA (mm²) (leg) 0.31 30 0.0014 
Leg: Polar moment of inertia tibia (mm⁴) to MA (mm²) 
(leg) 0.47 27 <0.0001 
Leg: SSI tibia (mm³) to MA (mm²) (leg) 0.52 27 <0.0001 
Leg: Fat area (mm²) to MA (mm²) (leg) 0.022 28 0.45 
Leg: Muscle density (mg/mL) to MA (mm²) (leg) 0.0015 27 0.85 
MIGF of non-dominant hand (N) to MA (mm²) (leg) 0.36 26 0.00030 
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TABLE 15: Correlation to pQCT muscle area (arm/leg) of various pQCT parameters, MIGF 
and DXA bone mass with R², N, p by time from GH start; 12 months 
Time from GH start (mo) 12 
Correlation to muscle area (mm²) of R² N 
p Value 
MA 
Total CSA (mm²) to MA (mm²) (arm) 0.28 41 0.00040 
Cortical CSA radius (mm²) to MA (mm²) (arm) 0.60 41 <0.0001 
Cortical thickness (mm) to MA (mm²) (arm) 0.31 41 0.00010 
Total vBMD (mg/cm³) to MA (mm²) (arm) 0.11 41 0.031 
Cortical content radius (mg/mm) to MA (mm²) (arm) 0.57 41 <0.0001 
Cortical vBMD (mg/cm³) to MA (mm²) (arm) 0.20 41 0.0034 
Polar moment of inertia radius (mm⁴) to MA (mm²) (arm) 0.57 41 <0.0001 
SSI radius (mm³) to MA (mm²) (arm) 0.79 41 <0.0001 
Fat area (mm²) to MA (mm²) (arm) 0.00057 41 0.88 
Muscle density (mg/mL) to MA (mm²) (arm) 0.011 41 0.51 
DXA bone mass (g) to MA (mm²) (arm) 0.35 11 0.054 
DXA: Bone mineral density (g/cm²) to MA (mm²) (arm) 0.00045 11 0.95 
MIGF of non-dominant hand (N) to MA (mm²) (arm) 0.71 34 <0.0001 
Leg: Total CSA tibia (mm²) to MA (mm²) (leg) 0.711 40 <0.0001 
Leg: Cortical CSA tibia (mm²) to MA (mm²) (leg) 0.76 37 <0.0001 
Leg: Cortical thickness tibia (mm) to MA (mm²) (leg) 0.44 37 <0.0001 
Leg: Total vBMD (mg/cm³) to MA (mm²) (leg) 0.099 40 0.048 
Leg: Cortical content tibia (mg/mm) to MA (mm²) (leg)  0.73 37 <0.0001 
Leg: Cortical vBMD tibia (mg/cm³) to MA (mm²) (leg) 0.078 40 0.081 
Leg: Polar moment of inertia tibia (mm⁴) to MA (mm²) 
(leg) 0.79 37 <0.0001 
Leg: SSI tibia (mm³) to MA (mm²) (leg) 0.79 37 <0.0001 
Leg: Fat area (mm²) to MA (mm²) (leg) 0.23 37 0.0024 
Leg: Muscle density (mg/mL) to MA (mm²) (leg) 0.0071 35 0.63 
MIGF of non-dominant hand (N) to MA (mm²) (leg) 0.55 32 <0.0001 
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TABLE 16: Correlation to pQCT muscle area (arm/leg) of various pQCT parameters, MIGF 
and DXA bone mass with R², N, p by time from GH start; 24 months 
Time from GH start (mo) 24 
Correlation to muscle area (mm²) of R² N 
p Value 
MA 
Total CSA (mm²) to MA (mm²) (arm) 0.30 21 0.010 
Cortical CSA radius (mm²) to MA (mm²) (arm) 0.36 21 0.0040 
Cortical thickness (mm) to MA (mm²) (arm) 0.11 21 0.15 
Total vBMD (mg/cm³) to MA (mm²) (arm) 0.011 21 0.64 
Cortical content radius (mg/mm) to MA (mm²) (arm) 0.33 21 0.0069 
Cortical vBMD (mg/cm³) to MA (mm²) (arm) 0.0090 21 0.68 
Polar moment of inertia radius (mm⁴) to MA (mm²) (arm) 0.43 21 0.0012 
SSI radius (mm³) to MA (mm²) (arm) 0.67 21 <0.0001 
Fat area (mm²) to MA (mm²) (arm) 0.25 23 0.015 
Muscle density (mg/mL) to MA (mm²) (arm) 0.078 22 0.21 
DXA bone mass (g) to MA (mm²) (arm) 0.97 5 0.0027 
DXA: Bone mineral density (g/cm²) to MA (mm²) (arm) 0.22 5 0.42 
MIGF of non-dominant hand (N) to MA (mm²) (arm) 0.40 19 0.0034 
Leg: Total CSA tibia (mm²) to MA (mm²) (leg) 0.72 21 <0.0001 
Leg: Cortical CSA tibia (mm²) to MA (mm²) (leg) 0.74 20 <0.0001 
Leg: Cortical thickness tibia (mm) to MA (mm²) (leg) 0.16 20 0.076 
Leg: Total vBMD (mg/cm³) to MA (mm²) (leg) 0.034 21 0.43 
Leg: Cortical content tibia (mg/mm) to MA (mm²) (leg)  0.70 20 <0.0001 
Leg: Cortical vBMD tibia (mg/cm³) to MA (mm²) (leg) 0.034 21 0.42 
Leg: Polar moment of inertia tibia (mm⁴) to MA (mm²) 
(leg) 0.80 20 <0.0001 
Leg: SSI tibia (mm³) to MA (mm²) (leg) 0.70 20 <0.0001 
Leg: Fat area (mm²) to MA (mm²) (leg) 0.00037 21 0.93 
Leg: Muscle density (mg/mL) to MA (mm²) (leg) 0.0094 21 0.68 
MIGF of non-dominant hand (N) to MA (mm²) (leg) 0.48 19 0.00050 
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TABLE 17: Correlation to pQCT muscle area (arm/leg) of various pQCT parameters, MIGF 
and DXA bone mass with R², N, p by time from GH start; 36 months 
Time from GH start (mo) 36 
Correlation to muscle area (mm²) of R² N 
p Value 
MA 
Total CSA (mm²) to MA (mm²) (arm) 0.73 17 <0.0001 
Cortical CSA radius (mm²) to MA (mm²) (arm) 0.75 17 <0.0001 
Cortical thickness (mm) to MA (mm²) (arm) 0.48 17 0.0021 
Total vBMD (mg/cm³) to MA (mm²) (arm) 0.015 17 0.64 
Cortical content radius (mg/mm) to MA (mm²) (arm) 0.70 17 <0.0001 
Cortical vBMD (mg/cm³) to MA (mm²) (arm) 0.14 17 0.14 
Polar moment of inertia radius (mm⁴) to MA (mm²) (arm) 0.78 17 <0.0001 
SSI radius (mm³) to MA (mm²) (arm) 0.75 17 <0.0001 
Fat area (mm²) to MA (mm²) (arm) 0.11 17 0.19 
Muscle density (mg/mL) to MA (mm²) (arm) 0.11 17 0.19 
DXA bone mass (g) to MA (mm²) (arm) 0.91 4 0.047 
DXA: Bone mineral density (g/cm²) to MA (mm²) (arm) 0.77 4 0.12 
MIGF of non-dominant hand (N) to MA (mm²) (arm) 0.92 9 <0.0001 
Leg: Total CSA tibia (mm²) to MA (mm²) (leg) 0.84 15 <0.0001 
Leg: Cortical CSA tibia (mm²) to MA (mm²) (leg) 0.50 15 0.0031 
Leg: Cortical thickness tibia (mm) to MA (mm²) (leg) 0.061 15 0.38 
Leg: Total vBMD (mg/cm³) to MA (mm²) (leg) 0.084 15 0.29 
Leg: Cortical content tibia (mg/mm) to MA (mm²) (leg)  0.42 15 0.0083 
Leg: Cortical vBMD tibia (mg/cm³) to MA (mm²) (leg) 0.011 15 0.71 
Leg: Polar moment of inertia tibia (mm⁴) to MA (mm²) 
(leg) 0.93 15 <0.0001 
Leg: SSI tibia (mm³) to MA (mm²) (leg) 0.76 15 <0.0001 
Leg: Fat area (mm²) to MA (mm²) (leg) 0.12 15 0.21 
Leg: Muscle density (mg/mL) to MA (mm²) (leg) 0.00073 13 0.93 
MIGF of non-dominant hand (N) to MA (mm²) (leg) 0.83 9 0.0005 
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TABLE 18: Correlation to pQCT muscle area (arm/leg) of various pQCT parameters, MIGF 
and DXA bone mass with R², N, p by time from GH start; 48 months 
Time from GH start (mo) 48 
Correlation to muscle area (mm²) of R² N 
p Value 
MA 
Total CSA (mm²) to MA (mm²) (arm) 0.75 9 0.0025 
Cortical CSA radius (mm²) to MA (mm²) (arm) 0.92 9 <0.0001 
Cortical thickness (mm) to MA (mm²) (arm) 0.58 9 0.018 
Total vBMD (mg/cm³) to MA (mm²) (arm) 0.096 9 0.42 
Cortical content radius (mg/mm) to MA (mm²) (arm) 0.91 9 <0.0001 
Cortical vBMD (mg/cm³) to MA (mm²) (arm) 0.25 9 0.17 
Polar moment of inertia radius (mm⁴) to MA (mm²) (arm) 0.70 9 0.0047 
SSI radius (mm³) to MA (mm²) (arm) 0.84 9 0.00050 
Fat area (mm²) to MA (mm²) (arm) 0.10 10 0.37 
Muscle density (mg/mL) to MA (mm²) (arm) 0.10 10 0.37 
DXA bone mass (g) to MA (mm²) (arm) 0.99 3 0.058 
DXA: Bone mineral density (g/cm²) to MA (mm²) (arm) 0.30 3 0.63 
MIGF of non-dominant hand (N) to MA (mm²) (arm) 0.85 5 0.027 
Leg: Total CSA tibia (mm²) to MA (mm²) (leg) 0.82 8 0.0021 
Leg: Cortical CSA tibia (mm²) to MA (mm²) (leg) 0.92 7 0.00020 
Leg: Cortical thickness tibia (mm) to MA (mm²) (leg) 0.59 7 0.045 
Leg: Total vBMD (mg/cm³) to MA (mm²) (leg) 0.19 8 0.29 
Leg: Cortical content tibia (mg/mm) to MA (mm²) (leg)  0.88 7 0.00050 
Leg: Cortical vBMD tibia (mg/cm³) to MA (mm²) (leg) 0.35 8 0.12 
Leg: Polar moment of inertia tibia (mm⁴) to MA (mm²) 
(leg) 0.93 7 0.00010 
Leg: SSI tibia (mm³) to MA (mm²) (leg) 0.97 7 <0.0001 
Leg: Fat area (mm²) to MA (mm²) (leg) 0.31 5 0.33 
Leg: Muscle density (mg/mL) to MA (mm²) (leg) 0.61 3 0.43 
MIGF of non-dominant hand (N) to MA (mm²) (leg) 0.36 4 0.19 
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7.2 Figures 
7.2.1 Course of pQCT measurements (arm and leg) from start to 48 
months of GH-treatment in SGA boy 
The following figures (FIGURE 1 to FIGURE 12) show the course of pQCT 
measurements in arm and leg in a SGA boy under GH-treatment with good 
response to growth hormone starting at the age of six up to ten years. 
One can see the subcutaneous fat (dark grey) decrease and the muscle area 
(lighter grey) and bone surface area (white) increase with time under GH 
treatment. See progression from FIGURE 1 to FIGURE 6 for pQCT 
measurements of the arm and FIGURE 7 to FIGURE 12 for pQCT 
measurements of the leg from start to 48 months of GH treatment. These 
measurements show a good quality in all examinations during the 48 months of 
GH treatment with only few artifacts due to minor movements. 
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FIGURE 1: Child A: SGA, male; arm pQCT at start of GH-treatment  
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FIGURE 2: Child A: SGA, male; arm pQCT after 6 months on GH-treatment 
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FIGURE 3: Child A: SGA, male; arm pQCT after 12 months on GH-treatment 
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FIGURE 4: Child A: SGA, male; arm pQCT after 24 months on GH-treatment 
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FIGURE 5: Child A: SGA, male; arm pQCT after 36 months on GH-treatment 
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FIGURE 6: Child A: SGA, male; arm pQCT after 48 months on GH-treatment 
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FIGURE 7: Child A: SGA, male; leg pQCT at start of GH-treatment 
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FIGURE 8: Child A: SGA, male; leg pQCT after 6 months on GH-treatment 
 
62 
 
  
 
 
FIGURE 9: Child A: SGA, male; leg pQCT after 12 months on GH-treatment 
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FIGURE 10: Child A: SGA, male; leg pQCT after 24 months on GH-treatment 
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FIGURE 11: Child A: SGA, male; leg pQCT after 36 months on GH-treatment 
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FIGURE 12: Child A: SGA, male; leg pQCT after 48 months on GH-treatment 
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7.2.2 Excluded pQCT images 
The following FIGURE 13 shows pQCT measurements of an AGA girl (child B) 
aged five years, which had to be excluded, because the quality was too poor for 
further analysis. Fat, muscle and bone area could not be correctly distinguished 
by the software of Stratec for pQCT analysis. In the result the calculated value 
for muscle area was negative and the values for fat area and total area were 
almost the same. Unfortunately, this child had to be excluded from the study, 
because without useful data of the starting point of GH-treatment the including 
criteria could not be met. FIGURE 14 shows the courses of pQCT parameters 
(total area, fat area, muscle area and percentage of muscle area) during GH 
treatment. Spikes are for muscle area and fat area at start. 
A similar situation occurred in the measurements at start of an SGA boy (child 
C) aged five years as shown in FIGURE 15 and FIGURE 16. FIGURE 16 shows 
spikes in muscle area, fat area and muscle area (%) at start. He also had to be 
excluded from the study. 
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FIGURE 13: Child B: AGA, female; arm pQCT at start of GH-treatment 
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FIGURE 14: Child B: AGA, female; courses of pQCT measurements during GH treatment 
(x-axis: time from GH start in months; y-axis: various pQCT parameters) 
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FIGURE 15: Child C: SGA, male; arm pQCT at start of GH-treatment 
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FIGURE 16: Child C: SGA, male; courses of pQCT measurements during GH treatment (x-
axis: time from GH start in months; y-axis: various pQCT parameters) 
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7.2.3 Examples of pQCT images with poor quality  
The following figures show examples of pQCT measurements in arm and leg 
with poor quality due to minor movements during investigation. Results of the 
calculations for muscle, fat and bone area were still acceptable with no negative 
results as shown in the example above (FIGURE 13 to FIGURE 16). These 
measurements were not excluded from the study, because otherwise the study 
group would have been too small to allow any statistical conclusions.  
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FIGURE 17: Child D: SGA, male; arm pQCT at start of GH-treatment 
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FIGURE 18: Child E: SGA, female; arm pQCT at start of GH-treatment 
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FIGURE 19: Child E: SGA, female; arm pQCT after 12 months on GH-treatment 
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FIGURE 20: Child F: AGA, male; arm pQCT at start of GH-treatment 
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FIGURE 21: Child F: AGA, male; leg pQCT at start of GH-treatment 
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FIGURE 22: Child G: AGA, male; leg pQCT at start of GH-treatment 
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FIGURE 23: Child G: AGA, male; leg pQCT after 12 months on GH-treatment 
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7.2.4 The correlation of various parameters to muscle cross-sectional 
area of the arm 
The comparison of different bone parameters as well as maximal isometric grip 
force [N], fat area [mm²] and muscle density [mg/mL] according to their 
dependency on muscle area [mm²] in arms and legs respectively by a 
regression analysis at start of GH therapy is given in the diagrams below. Their 
longitudinal progressions are shown in separate diagrams and with the results 
listed in TABLE 13-18 (see appendix). 
 
FIGURE 24: Total CSA by pQCT to MA (arm) by pQCT at GH start 
 
FIGURE 25: Cortical CSA by pQCT to MA (arm) by pQCT at GH start  
 = AGA 
 = SGA 
 = AGA 
 = SGA 
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FIGURE 26: Cortical thickness by pQCT to MA (arm) by pQCT at GH start 
 
 
FIGURE 27: Total vBMD by pQCT to MA (arm) by pQCT at GH start 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
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FIGURE 28: Cortical content by pQCT to MA (arm) by pQCT at GH start 
 
 
FIGURE 29: Cortical vBMD by pQCT to MA (arm) by pQCT at GH start 
 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
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FIGURE 30: Polar moment of inertia by pQCT to MA (arm) by pQCT at GH start 
 
FIGURE 31: SSI by pQCT to MA (arm) by pQCT at GH start 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
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FIGURE 32: DXA Bone mass to MA (arm) by pQCT at GH start  
 
 
FIGURE 33: DXA Bone mineral density to MA (arm) by pQCT at GH start 
 
Bone mineral density [g/cm²] measured by DXA (complete body scan) refers to 
the amount of mineral in the entire bone regions studied and is dependent of 
the measured bone size as described above for bone mineral content by DXA.  
In DXA bone mineral content (BMC) is used in a different way than in pQCT. In 
DXA BMC refers to the amount of mineral in the entire bone regions studied. 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
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This is influenced by bone length or the size of the analyzed region. In pQCT 
BMC is the mass of mineral per axial bone length (mg/mm) 23. 
 
  
FIGURE 34: MIGF by Jamar dynamometer to MA (arm) by pQCT in the right and left hand 
at GH start 
 
 
FIGURE 35: Fat area by pQCT to MA (arm) by pQCT at GH start 
 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
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FIGURE 36: Muscle density by pQCT to MA (arm) by pQCT at GH start 
 
  
 = AGA 
 = SGA 
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FIGURE 37 shows the correlation of muscle area in leg to different leg pQCT 
parameters corresponding to the above shown figures of correlations to arm 
pQCT parameters. 
TABLE 13-18 list the longitudinal progression of the correlation to muscle area 
in arm and leg of the best correlating parameters of pQCT, DXA bone mass and 
MIGF with the coefficient R², N and the level of significance p. 
The parameters that correlate best with muscle area of the arm are SSI with 
R² = 0.78 and polar moment of inertia with R² = 0.76 followed by cortical CSA 
with R² = 0.61, cortical content with R² = 0.59, total CSA with R² = 0.54 and 
cortical thickness with R² = 0.36 (all with p < 0.0001). MIGF of the non-dominant 
hand correlates to muscle area with R² = 0.56 (p < 0.0001). Total vBMD 
correlates to muscle area of the arm with R² = 0.15 (p = 0.018) and cortical 
vBMD with R² = 0.24 (p = 0.0017). DXA bone mass correlates to muscle area of 
the arm with R² = 0.66 with p = 0.00070. Fat area, muscle density and DXA 
bone mineral density do not show significance when correlated to muscle area 
of the arm. 
Best correlating parameters to muscle area of the leg are SSI with R² = 0.73, 
cortical CSA with R² = 0.67, followed by cortical content and polar moment of 
inertia both with R² = 0.64 and total CSA with R² = 0.49 (all with p < 0.0001). 
MIGF of the non-dominant hand shows a poorer correlation to muscle area of 
the leg than to arm with R² = 0.50 (p < 0.001). Cortical thickness of the tibia 
correlates to muscle area of the leg with R² = 0.33 (p = 0.00030) and fat area 
with R² = 0.15 (p = 0.018). No significance is found in the correlation of total 
vBMD, cortical vBMD and muscle density to muscle area of the leg. 
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7.2.5 Correlation of various parameters to muscle cross-sectional area of 
the leg. 
  
  
  
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
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FIGURE 37: Correlation of leg pQCT parameters to leg muscle area 
  
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
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7.2.6 Courses of best correlations to muscle area in arm and leg 
Time from GH start (mo.): 0 Time from GH start (mo.): 6 
 Time from GH start (mo.): 12  Time from GH start (mo.): 24 
 Time from GH start (mo.): 36  Time from GH start (mo.): 48 
  
FIGURE 38: Total CSA (radius) [mm²] to MA (arm) [mm²] 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
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Time from GH start (mo): 0 Time from GH start (mo): 6 
Time from GH start (mo): 12 Time from GH start (mo): 24 
Time from GH start (mo): 36 Time from GH start (mo): 48 
  
FIGURE 39: Cortical CSA (radius) [mm²] to MA (arm) [mm²] 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
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Time from GH start (mo.): 0 Time from GH start (mo.): 6 
 
Time from GH start (mo.): 12 
 
Time from GH start (mo.): 24 
 
Time from GH start (mo.): 36 
 
Time from GH start (mo.): 48 
  
FIGURE 40: Cortical thickness (radius) [mm] to MA (arm) [mm²] 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
 = AGA 
 = SGA 
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FIGURE 41: Total vBMD (radius) [mg/cm³] to MA (arm) [mm²] 
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FIGURE 42: Cortical content (radius) [mg/mm] to MA (arm) [mm²] 
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FIGURE 43: Cortical vBMD (radius) [mg/cm³] to MA (arm) [mm²] 
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FIGURE 44: Polar moment of inertia (arm) [mm⁴] to MA (arm) [mm²] 
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FIGURE 45: SSI (arm) [mm³] to MA (arm) [mm²] 
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FIGURE 46: Maximal isometric grip force of the non-dominant hand [N] to MA (arm) [mm²] 
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FIGURE 47: Total cross-sectional area (tibia) [mm²] to MA (leg) [mm²] 
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FIGURE 48: Cortical cross-sectional area (tibia) [mm²] to MA (leg) [mm²] 
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FIGURE 49: Cortical thickness (tibia) [mm] to MA (leg) [mm²] 
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FIGURE 50: Cortical content (tibia) [mg/mm] to MA(leg) [mm²] 
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FIGURE 51: Polar moment of inertia (leg) [mm⁴] to MA (leg) [mm²] 
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FIGURE 52: SSI (leg) [mm³] to MA (leg) [mm²] 
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FIGURE 53: Fat area (leg) [mm²] to MA (leg) [mm²] 
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FIGURE 54: Maximal isometric grip force of the non-dominant hand [N] to MA (leg) [mm²] 
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FIGURE 55: DXA Bone mass [g] to MA (arm) [mm²] 
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7.2.7 Courses of bone and tissue values in arm and leg pQCT to age 
Changes of various pQCT parameters to age (y) under GH treatment are shown 
in the following figures for arm and leg measurements separately. Total area, 
muscle area, fat area, total cross-sectional area and cortical cross-sectional 
area of radius and tibia respectively are correlated to age. Courses of fat area 
do not show any uniformity in arm and leg measurements. Fat area is not a 
useful parameter to examine changes under GH treatment when not set in 
relation to whole body composition. On the one hand changes in fat area are 
subjected to a decrease under GH treatment and on the other hand to an 
increase over time with increasing total weight. 
pQCT measurements in this study show better results in leg measurements 
than in arm measurements. Even slight movements during the measuring 
process reduce the quality, which occurs more often in arm than in leg 
measurements. The courses of total area (leg), muscle area (leg), total cross-
sectional area (tibia) and cortical cross-sectional area (tibia) to age show 
smoother increments than the equivalent measurements of the arm. Differences 
are especially clear in bone parameters having the smallest surface values.  
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FIGURE 56: Total area (mm²) to age (y) (arm and leg pQCT) 
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FIGURE 57: Muscle area (mm²) to age (y) (arm and leg pQCT) 
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FIGURE 58: Fat area (mm²) to age (y) (arm and leg pQCT) 
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FIGURE 59: Total CSA (mm²) to age (y) (arm and leg pQCT) 
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FIGURE 60: Cortical CSA (mm²) to age (y) (arm and leg pQCT) 
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8 Deutsche Zusammenfassung 
Titel: Größe, Muskel- und Fettmasse sowie Knochenzusammensetzung unter 
Wachstumshormonbehandlung bei ehemaligen früh- und mangelgeborenen 
Kindern und SGA Kindern mit einem Geburtsgewicht bis 1500 g sowie 
fehlendem Aufholwachstum.  
Hintergrund: Ein Teil der SGA (small for gestational age: zu klein in Bezug auf 
das Gestationsalter) geborenen Kinder und ein Teil der unreif AGA (appropriate 
for gestational age: normal groß in Bezug auf das Gestationsalter) geborenen 
Kinder mit einem Geburtsgewicht bis 1500 g werden zu kleinwüchsigen Kindern 
und weisen einen Mangel an Muskelmasse und –kraft auf. Eine 
Wachstumshormonbehandlung ist bisher nur für kleine SGA Kinder zugelassen, 
jedoch nicht für kleine AGA Kinder mit einem Geburtsgewicht bis 1500 g. 
Zielsetzung: Diese Studie untersucht, wie sich eine 
Wachstumshormonbehandlung auf Größenzuwachs, Muskelmasse, –kraft 
sowie Knochendichte und –geometrie an kleinen SGA und AGA Kindern mit 
einem Geburtsgewicht bis 1500 g auswirkt. 
Studiendesign: Diese longitudinale Kontrollstudie wurde in der Abteilung für 
Pädiatrische Endokrinologie und Diabetologie der Kinderklinik des 
Universitätsklinikum Tübingen durchgeführt. Daten wurden zu Beginn und 
während des ersten Behandlungsjahres erhoben, in einigen Fällen darüber 
hinaus. 
Patientengruppe: Die Patientengruppe besteht aus 44 präpubertären kleinen 
Kindern mit einem Geburtsgewicht unter 1500 g. Die Gruppe teilt sich in 17 
SGA Kinder (6 Mädchen) und 27 AGA Kinder (12 Mädchen) auf. Die 
Berechnung der Mittelwerte zum Therapiebeginn ergab: Alter 6.9 J. AGA; 7.1 J. 
SGA; Größe SDS -3.3 AGA; -3.3 SGA; Knochenalter 5.8 J. AGA; 4.3 J. für SGA 
und Geburtsgewicht SDS -0.96 für AGA und -3.2 für SGA. 
Intervention: Die mittlere Wachstumshormondosis lag sechs Monate nach 
Behandlungsbeginn bei 54 µg/kg/d in der AGA Gruppe (SD 12) und 51 µg/kg/d 
in der SGA Gruppe (SD 11). 
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Methode: Mittels peripherer quantitativer Computertomografie (pQCT) (XCT 
2000; Stratec, Inc., Pforzheim, Germany) wurden die Querschnittsflächen von 
Unterarm und Unterschenkel gemessen. Daten zur Körperzusammensetzung 
von Fett-, Muskel- und Knochenmasse sowie Wassergehalt wurden mittels 
DXA-Scan und BIA gemessen. Die maximale isometrische Handkraft (MIGF) 
wurde mit dem Jamar Dynamometer (Preston, Jackson, MI) und die 
Hautfaltendicke mit dem Holtain/Tanner-Whitehouse Skinfold Caliper 
gemessen. Die IGF-1 und IGFBP-3 Werte wurden im Hormonlabor der 
Tübinger Kinderendokrinologie ermittelt. Alle Messdaten wurden zu Beginn der 
Wachstumshormontherapie, nach zwölf Monaten und in einigen Fällen darüber 
hinaus ermittelt. 
Ergebnisse: Zu Beginn der Wachstumshormonbehandlung wiesen beide 
Gruppen gleiche Charakteristika im Wachstumsverhalten auf. Größe, Gewicht 
und Wachstumsgeschwindigkeit waren erniedrigt. Muskelmasse und 
Knochendicke und –dichte waren erniedrigt, jedoch gleich in der AGA und SGA 
Gruppe. Beide Gruppen zeigten unter Wachstumshormonbehandlung eine 
ähnliche Zunahme an Größe und Gewicht. Im ersten Jahr unter 
Wachstumshormonbehandlung stieg der SDS der Muskelfläche von -2.2 auf 
-0.73 in der AGA Gruppe (p = 0.0010) und von -3.2 auf -1.2 in der SGA Gruppe 
(p = 0.060), (AGA vs. SGA p = 0.61); der SDS der Fettfläche fiel von -1.1 auf 
-1.8 in der AGA Gruppe (p = 0.054) und von -0.62 auf -1.7 in der SGA Gruppe 
(p = 0.12), (AGA vs. SGA p = 0.65) und der SDS der 
Wachstumsgeschwindigkeit stieg in der AGA Gruppe von -0.0015 auf 4.2 
(p < 0.0001), in der SGA Gruppe von -0.18 auf 3.3 (p < 0.0001), (AGA vs. SGA 
p = 0.36). Veränderungen im größenabhängigen-SDS für Kortikalisdichte und 
im größen- und altersabhängigen SDS für Fettfläche in der AGA Gruppe waren 
statistisch signifikant. Die Veränderungen unter 
Wachstumshormonbehandlungen während des ersten Jahres ergaben im 
Vergleich beider Gruppen miteinander keine signifikanten Unterschiede. Die 
Auswertungen der pQCT Messungen des Beines konnten nicht in SDS 
dargestellt werden, da bisher keine Normalwerte für diese Messungen an 
Kindern existieren. SSI, polares Trägheitsmoment, Kortikalisfläche, 
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Mineralgehalt der Kortikalis und MIGF zeigten eine positive Korrelation mit 
Muskelfläche der Arm- und Bein pQCT Messungen zu Beginn und während der 
Wachstumshormonbehandlung. 
Zusammenfassung: Präpubertäre Kinder mit fehlendem Aufholwachstum und 
einem niedrigen Geburtsgewicht weisen, unabhängig davon ob sie zu klein oder 
normal groß für ihr Geburtsalter waren, ein gleichermaßen eingeschränktes 
Wachstum und veränderte Körperzusammensetzung der Muskel- und 
Knochenparameter auf.  
Die zwei Gruppen unterscheiden sich nicht hinsichtlich ihres Ansprechens auf 
eine Wachstumshormonbehandlung. Insofern erscheint die Zulassung einer 
Wachstumshormonbehandlung für SGA Kinder aber nicht für AGA Kinder bei 
einem Geburtsgewicht unter 1500 g arbiträr.   
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